The role of mtDNA damage in mitochondrial dysfunction by Furda, Amy Marie
 The role of mtDNA damage in mitochondrial dysfunction 
 
 
 
 
 
 
 
 
by 
Amy Marie Furda 
B.S. Biology, Bethany College, 2006 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
University of Pittsburgh School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
   
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This dissertation was presented 
by 
 
 
Amy Marie Furda 
 
 
 
It was defended on 
December 8th, 2011 
and approved by 
Chairperson: Guillermo Romero, Ph.D., Associate Professor, Department of Pharmacology & 
Chemical Biology 
Laura Niedernhofer, M.D., Ph.D., Associate Professor, Department of Microbiology & 
Molecular Genetics 
Alicia Palladino, Ph.D., Research Assistant Professor, Department of Pharmacology & 
Chemical Biology 
Sruti Shiva, Ph.D., Assistant Professor, Department of Pharmacology & Chemical Biology 
Robert W. Sobol, Ph.D., Assistant Professor, Department of Pharmacology & Chemical 
Biology 
 Dissertation Advisor: Bennett Van Houten, Ph.D., Professor, Department of Pharmacology & 
Chemical Biology 
 
 
 iii 
Copyright © by Amy Marie Furda 
2011 
 iv 
 
Mammalian mitochondria have a 16.5 kb genome encoding for 13 polypeptides, 2 
rRNAs, and 22 tRNAs essential for mitochondrial function.  Mutations and deletions in 
mitochondrial DNA (mtDNA) are implicated in some hereditary diseases as well as aging, 
cancer and neurodegeneration.  Here, we examine the role of DNA ligase in mtDNA 
maintenance, and the role of mtDNA damage inflicted by hydrogen peroxide (H2O2) or methyl 
methanesulfonate (MMS) in mitochondrial dysfunction. We establish that mitochondrial DNA 
ligase activity is essential for survival, persistent mtDNA damage is not sufficient to induce rapid 
mtDNA loss and mitochondrial dysfunction.  We removed and replaced the normal 
mitochondrial DNA ligase III with different forms of mitochondrially-targeted DNA ligase, and 
found that mitochondrial DNA ligase activity is necessary for cellular survival and that any type 
of DNA ligase activity in the mitochondria is sufficient to maintain mtDNA integrity and copy 
number.  To study the relationship between mtDNA integrity and mitochondrial function, we 
treated cells with H2O2 or with the alkylating agent MMS, both of which resulted in persistent 
mtDNA lesions. However, only the H2O2-treated cells showed mtDNA loss and mitochondrial 
dysfunction by 8 hours post-treatment, indicating that persistent mtDNA damage does not 
necessarily cause a rapid loss of mtDNA or mitochondrial function.  These data suggest that 
oxidants are more efficient than alkylating agents at driving mtDNA loss and mitochondrial 
dysfunction. 
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We then addressed the cause of H2O2-induced loss of mtDNA 8 hours following 
treatment.  We hypothesized that this loss of mtDNA is dependent upon mitochondrial fission 
and mitophagy.  In order to test this hypothesis, we treated cells with the fission inhibitor mdivi-
1. Mdivi-1 protected mtDNA against oxidative-induced mtDNA damage but not MMS-induced 
mtDNA damage.  Because mdivi-1 is thought to act through inhibition of Drp1, we performed 
siRNA-mediated knockdown (KD) of Drp1 and observed that the knockdown did not 
recapitulate mdivi-1 treatment in protecting against H2O2-induced mtDNA damage.  
Furthermore, treating Drp1 KD cells with mdivi-1 still showed the protective effects of mdivi-1 
on mtDNA damage. These results suggest that the mdivi-1 mediated protection of oxidant-
induced mtDNA damage may be independent of its role in inhibiting mitochondrial fission.   
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1.0  INTRODUCTION 
1.1 MITOCHONDRIAL STRUCTURE 
Mitochondria are double-membrane organelles located in the cytoplasm of most 
mammalian cells.  Their outer membrane contains transporters such as porin (VDAC-1) and the 
translocase of the outer membrane (TOM)(1).  Between the outer and inner membranes of 
mitochondria is an intermembrane space with enzymes such as copper,zinc-superoxide 
dismutase (Cu,Zn-SOD)(2) and cytochrome c (3) as well as an accumulation of protons that 
establish an electrochemical gradient across the impermeable inner membrane.  Embedded 
within the inner membrane are inner membrane translocases (TIM) and the complexes of the 
electron transport chain, which participate in ATP production via oxidative phosphorylation (1).  
The innermost space of the mitochondria is the matrix, which in humans contains 2-10 copies of 
the mitochondrial genome (mtDNA), a circular 16.5 kb molecule (4) as well as matrix 
antioxidants.  The mtDNA is not protected by histones like nuclear DNA (nDNA) and is instead 
associated with the protein mitochondrial transcription factor A (TFAM) and single-strand 
binding proteins (5).  The mitochondrial genome encodes 13 polypeptides, 22 transfer RNAs and 
2 ribosomal RNAs; these gene products are essential for oxidative phosphorylation.  The 
mitochondrial DNA polymerase, Pol γ, is encoded by the nucleus and is involved in both DNA 
replication and repair. 
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1.2 OXIDATIVE PHOSPHORYLATION 
ATP production in the mitochondria is carried out through the process of oxidative 
phosphorylation.  This is accomplished by a series of five complexes embedded in the inner 
mitochondrial membrane and involves the acceptance of electrons from the reducing agents 
nicotinamide adenine dinucleotide (NADH) or flavine adenine dinucleotide (FADH2) at 
Complex I and Complex II, respectively.  These electrons are passed along the complexes by 
electron carriers such as ubiquinone and cytochrome c.   Concurrently with electron transport, 
protons are transferred across the inner membrane by complex I (NADH dehydrogenase), 
complex III (cytochrome bc 1 complex), and complex IV (cytochrome c oxidase).  The transfer 
of protons to the intermembrane space establishes an electrochemical proton gradient due to the 
pH difference between the mitochondrial matrix and the intermembrane space  (reviewed in (6)).  
Complex V (ATP synthase) harnesses the proton gradient to produce ATP (reviewed in (7)).   
The ATP synthase can also run in reverse, converting ATP to ADP in an attempt to restore the 
proton gradient in the intermembrane space (reviewed in (7)).  Molecular oxygen is the final 
electron acceptor during oxidative phosphorylation and is reduced to water in a four-electron 
reduction.   
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1.3 MITOCHONDRIA AND ROS 
1.3.1 Mitochondrial ROS 
The two major forms of ROS in the mitochondria are superoxide and H2O2.  These are 
produced normally during oxidative phosphorylation and are increased during ischemia-
reperfusion and other instances of oxidative stress (8).  In the mitochondrial matrix the normal 
steady-state concentration of superoxide (O2•-) is estimated to be 5- to 10-fold higher than it is in 
the cytoplasm and nucleus (9,10).   
Mitochondrial superoxide is generated during respiratory chain activity (Scheme 1, 
reaction 1).  Superoxide is reduced to H2O2 by manganese superoxide dismutase (MnSOD) and 
copper,zinc superoxide dismutase (Cu,ZnSOD) in the mitochondria (Scheme 1, reaction 4) and is 
oxidized to molecular oxygen by cytochrome c (Scheme 1, reaction 3) or by molecules 
containing ferric iron, such as FeS-containing proteins (Scheme 1, reaction 2)(reviewed in (9)). 
Mitochondrial H2O2 is generated via SOD activity (Scheme 1, reaction 4) and by the 
spontaneous dismutation of superoxide (reviewed in (10)). Hydrogen peroxide is converted to 
water by glutathione peroxidase (Scheme 1, reaction 5) and peroxiredoxins (Scheme 1, reaction 
6)(reviewed in (9)).  When H2O2 reacts with Fe2+, the hydroxyl radical (HO) is generated via 
the Fenton reaction (Scheme 1, reaction 7).  The hydroxyl radical is highly reactive with all 
biomolecules, including nucleic acids, proteins, lipids, and sugars.  The reactions and processes 
that generate superoxide, H2O2, and the hydroxyl radical are summarized in scheme 1. 
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Scheme 1. Chemical reactions in mitochondrial ROS production and metabolism 
 
1.3.2 Mitochondrial antioxidant defense system. 
MnSOD (SOD2) is the primary enzymatic defense against superoxide produced during 
mitochondrial oxidative phosphorylation.  Each of the three SODs existing in mammalian cells 
have been knocked out, but it was the loss of SOD2 activity that had the most severe effects, 
including neonatal lethality, heart defects, and reduced activity of mitochondrial proteins, 
including complex I, complex II, aconitase, and citrate synthase (11-13).  In humans, 
polymorphisms in the Sod2 gene have been linked to several diseases including type I diabetes 
and various cancers (14-16), and in recent years SOD2 has been suggested to be a tumor 
suppressor (17). The intermembrane space of mitochondria typically contains Cu,Zn-SOD 
(SOD1) (2), which converts superoxide in the intermembrane space to H2O2. 
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Mitochondria have both glutathione peroxidase (GPX) and phospholipid hydroperoxide 
glutathione peroxidase (PHGPX) activity, which detoxifies H2O2 and oxidized lipids, 
respectively.  GPX activity appears to outcompete all other H2O2 scavengers in mitochondria 
(18).  In reducing H2O2, glutathione peroxidases generate oxidized glutathione (GSSG), which is 
re-reduced using the enzyme glutathione reductase and the reducing agent NADPH (reviewed in 
(6)). 
In addition to glutathione peroxidase and glutathione to reduce H2O2, mitochondria 
contain peroxiredoxins, which are small thiol-dependent peroxidases (19).  At least six isoforms 
of peroxiredoxin exist in humans, and these isoforms differ in their cellular location, their 
oligomeric status, and the presence of one or two conserved cysteines required for their function 
(20,21).  The mitochondrial isoforms of peroxiredoxin are peroxiredoxin-III and V (19).  Both of 
these mitochondrial isoforms utilize two conserved cysteine residues to reduce H2O2 to H2O and 
return the enzyme to its reduced state.  Peroxiredoxin-V overexpression in particular has been 
shown to protect mtDNA against exogenously added H2O2 (19). 
 Glutathione (GSH) is the major endogenous antioxidant and participates directly 
in reducing free radicals and ROS, keeping exogenous antioxidants such as vitamins E and C in 
their reduced forms, and directly binding xenobiotics and carcinogens (reviewed in (22)).  The 
reduced form of glutathione (GSH) makes up 90% of the glutathione pool in healthy cells and 
tissue (23).  There are two major pools of glutathione in the cell: the cytosolic pool and the 
mitochondrial pool (24).  The mitochondrial pool of glutathione composes 10-15% of the total 
cellular glutathione at a concentration similar to that of cytosolic glutathione (10-14 
mM)(reviewed in (22)).  After GSH reacts with an oxidant in a direct or glutathione peroxidase-
catalyzed reaction, the oxidized form of glutathione readily reacts with another molecule of 
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glutathione to form GSSG, thus preventing oxidants from damaging important biomolecules.  In 
fact, an increased GSSG-to-GSH ratio is considered to be an indication of oxidative stress (25). 
In addition to the antioxidant Cu,Zn-SOD  (2), the intermembrane space of mitochondria 
contains cytochrome c, which in its oxidized form (cyt c-Fe3+) can oxidize superoxide to 
molecular oxygen (reviewed in (26)).  
Though catalase is chiefly known for its role in the peroxisome and to a lesser extent in 
the cytoplasm, it has been detected in the mitochondria of rat heart and liver (27-29).  However, 
its presence in the mitochondria and its role there remains controversial (27).   
1.3.3 Sources of mitochondrial ROS 
Several superoxide-generating sites in mitochondria have been discovered by using 
inhibitors of the electron transport chain on isolated mammalian mitochondria or 
submitochondrial particles (reviewed in (10)).  Unlike when using intact mitochondria, 
submitochondrial particles are mainly devoid of the mitochondrial matrix antioxidant enzymes 
(30,31), and so ROS are not metabolized by the matrix antioxidants and are able to be detected 
and measured.  In this same vein, studies in isolated mitochondria do not take into account the 
effects of cytosolic antioxidants and other cellular components in the production and metabolism 
of mitochondrially-generated ROS.  Therefore, measurements made of mitochondrial ROS 
generation rates in vivo under normal conditions are indirect ((32), reviewed in (6)). 
An increase in ROS can be seen experimentally by treating cells with rotenone.  
Rotenone inhibits complex I by blocking the enzyme near the binding site for its electron 
acceptor ubiquinone (33).  This inhibition increases the reduction of complex I’s NADH 
dehydrogenase site, which faces the matrix side of the inner mitochondrial membrane (34), 
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leading to enhanced electron leak and superoxide production in that compartment (35).  
Rotenone treatment of intact mitochondria with complex I substrates does not lead to increased 
H2O2 production, and yet in submitochondrial particles, H2O2 production was increased, 
indicating that (1) complex I is the source of rotenone-induced ROS production and that (2) the 
ROS produced by complex I are metabolized by matrix antioxidants (36).  ROS produced by 
complex I are released into the mitochondrial matrix and can then cause mitochondrial damage 
or be inactivated by matrix antioxidants (30,37).  The specific sites of complex I that generate 
superoxide are proposed to be the NADH-binding site (site IF) and the ubiquinone reduction site 
(site IQ), but these sites still remain controversial (10). 
 Treatment of cells with 3-nitroproprionic acid as well as mutations in complex II 
have been shown to cause superoxide overproduction through complex II (38-40), but under 
normal conditions, superoxide from complex II is insignificant (10). 
Complex III is a major site of mitochondrial superoxide generation (41-44).  It has two 
main ROS-producing regions: the Qo center, which faces the intermembrane space; and the Qi 
center, which faces the mitochondrial matrix from its position in the inner mitochondrial 
membrane.  The complex III inhibitor antimycin A acts at the Qi center of complex III and 
increases superoxide production from the Qo center (42,44-46).  Unlike superoxide produced at 
the Qi site of complex III, which most likely is released into the mitochondrial matrix, 
superoxide produced at the Qo site of complex III is released into the mitochondrial 
intermembrane space (43,45,46).  Studies in both mitochondrial and submitochondrial particles 
using antimycin A to inhibit complex III increased H2O2 production, supporting the idea that 
superoxide produced at the Qo center is released into the intermembrane space and is not 
metabolized by matrix antioxidants (36,41).  Complex III is considered to be the dominant site of 
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mitochondrial ROS production, with 70% of the superoxide it generates released into the matrix 
and 30% released into the intermembrane space (36).   
Conversely, inhibiting complex IV does not lead to increased ROS production at complex 
IV (47-49) but causes increased electron leak and ROS production from complexes I and III (50).  
Studies of submitochondrial particles treated with the complex IV inhibitor azide suggest that 
complex I is the major site of ROS production in this case because H2O2 production was 
enhanced in the presence of complex I substrates, but not in the presence of the complex II 
substrate succinate and complex I inhibitor rotenone (36).   
 Though the flavoprotein monoamine oxidase is found on the mitochondrial outer 
membrane, its oxidative deamination of amines contributes to the steady-state concentration of 
H2O2 both in the cytosol and in the mitochondrial matrix (reviewed in (9)).  Hydrogen peroxide 
produced during the reaction between monoamine oxidase and catecholamines is proposed to 
damage the mitochondrial membrane and contribute to neurodegenerative diseases like 
Alzheimer’s and Parkinson’s (reviewed in (9)).   
 Another mitochondrial enzyme contributing to ROS production is glycerol-3-
phosphate dehydrogenase (GPDH), an enzyme present in tissues such as the brain, adipose 
tissue, heart muscle, placenta, and fibroblasts (51).  A cytosolic and mitochondrial isoform of 
GPDH work to oxidize NADH back to NAD+ and to recycle the byproducts.  The mitochondrial 
isoform of GPDH is located on the mitochondrial inner membrane facing the intermembrane 
space and is proposed to produce superoxide both in the mitochondrial intermembrane space and 
in the mitochondrial matrix, similar to complex III (52).   
 The matrix dehydrogenases pyruvate dehydrogenase and 2-oxoglutarate 
dehydrogenase also contribute to mitochondrial ROS, introducing superoxide species to the 
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mitochondrial matrix; however, the method of ROS production by these enzymes is poorly 
understood (10). 
1.3.4 The effects of ROS on biomolecules 
1.3.4.1 Effects of ROS on proteins 
 
Ferrous iron released from Fe-S clusters by superoxide readily binds both DNA and 
polypeptides, and so, when the Fenton reaction (Scheme 1, reaction 7) occurs at these sites, these 
proteins are expected to be damaged by the resultant hydroxyl radical (OH•)(53).  Of the wide 
variety of protein oxidation products, carbonyls are often measured as an indicator of protein 
oxidation due to their being most easily quantified (54).   The oxidation of most amino acids, 
aside from sulfur-containing residues, seems to be irreversible, and thus the oxidatively-modified 
protein likely undergoes proteolytic degradation.  The hydroxyl radical generated during Fenton 
chemistry targets cysteine and methionine more than other amino acid residues because these 
residues (1) readily react with hydroxyl radicals and (2) can be directly oxidized by H2O2 
without the involvement of Fenton chemistry (53,55).  In general, however, the speed of H2O2-
mediated cysteine and methionine oxidation is very low and thus, the direct oxidation of amino 
acids by H2O2 is unlikely to cause major effects at physiological H2O2 concentrations (56,57). 
Particular mitochondrial proteins shown to be inactivated by H2O2 include aconitase (58).  
Superoxide is also known to be highly reactive with the [4Fe-S] cluster in aconitase (9).  Another 
enzyme targeted by mitochondrial ROS is citrate synthase, and in fact there is a decrease in 
citrate synthase activity in the heart mitochondria of SOD2 mutant mice (13). 
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1.3.4.2 Effects of ROS on lipids 
 
The ROS-mediated oxidation of lipids is just one of three distinct methods of lipid 
peroxidation (LPO), the others being enzymatic oxidation and nonenzymatic oxidation by 
nonradical sources such ozone.   
Superoxide is not active enough to directly oxidize lipids, but when superoxide reacts 
with nitric oxide (NO•) to form peroxynitrite (ONOO-), this product is able to initiate lipid 
peroxidation (reviewed in (59)).  Superoxide may also indirectly contribute to LPO by reducing 
Fe3+ to Fe2+ (scheme 1, reaction 2), which can then react with H2O2 in the vicinity of lipids and 
generate hydroxyl radicals (scheme 1, reaction 7) that readily oxidize nearby lipids and other 
biomolecules.     
The reaction of ROS with lipids generates products that can be both detrimental and 
beneficial to the cell.  Lipid peroxidation can lead to biomembrane disturbances as well as 
protein and DNA modifications, but products of lipid peroxidation have been shown to regulate 
gene expression and redox signaling and enhance oxidative stress tolerance.  The lipid 
hydroperoxides resulting from lipid oxidation can become DNA-adducting electrophiles, thus 
propagating ROS damage (60)(reviewed in (61)).   
1.3.4.3 Effects of ROS on polysaccharides 
 
The effects of ROS on polysaccharides have been studied much more extensively in 
plants and fungi than in animals.  The major ROS that reacts with polysaccharides is the 
hydroxyl radical.  However, hyaluronic acid, a component of connective tissue in mammals, has 
been shown to be oxidatively depolymerized by H2O2 and Fe2+ in vitro [62].   
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1.3.4.4 Effects of ROS on nucleic acids 
 
Superoxide can only indirectly damage DNA by releasing ferrous iron (Fe2+) from Fe-S 
clusters.  This ferrous iron (Fe2+), some of which readily complexes with DNA, is directly 
oxidized by H2O2 in the Fenton reaction to generate the extremely reactive OH• (scheme 1, 
reaction 7)(62,63).  OH• reacts readily with all biomolecules near the site of its production at a 
rate limited only by diffusion, and when the site of OH• production is a ferrous iron-DNA 
complex, DNA damage results (53).  Guanine is a particular target of OH•, though OH• can 
attack any base (64).  The major product formed in an OH•-DNA reaction is 8-hydroxyguanine 
(8-oxoG), though other products can include thymine glycols, formamidopyrimidines, single-
strand breaks, and abasic sites.  Treatment of cells with H2O2 generates ten times more strand 
breaks and abasic sites in mtDNA than base substitutions (65). Mitochondrial DNA (mtDNA) is 
particularly susceptible to attack by oxygen radicals due to (1) its close proximity to the sites of 
superoxide production by the respiratory chain and (2) its lack of histone protection.  In fact, 
studies in which cells were treated with H2O2 at concentrations at 200 µM or less observed 
significantly more mtDNA damage than nuclear DNA (nDNA) damage (32,66-68), illustrating 
the increased ROS vulnerability of mtDNA compared to nDNA.   
1.3.5 ROS-associated pathologies 
A wide range of human diseases has been linked to oxidative stress and mitochondrial 
dysfunction, including cancers (breast, colorectal, gastric, kidney, etc.), diabetes mellitus, 
ischemia-reperfusion injury, atherosclerosis, and neurodegenerative diseases such as Alzheimer’s 
disease (AD), Lou Gehrig’s disease, Friedreich’s Ataxia, Huntington’s disease, and Parkinson’s 
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disease (reviewed in (8) and (69)).  Mutations in the mitochondrial genome and altered 
expression of mitochondrially-encoded proteins have been implicated in many of the 
aforementioned diseases (reviewed in (70-72)).  Alterations in mitochondrial mass, morphology, 
mtDNA copy number, and mitochondrial function have all been linked to neurodegenerative 
diseases.  For example, a decrease in mtDNA content and mitochondrial mass is an early 
indicator of Alzheimer’s disease (73,74).  Two studies generated cytoplasmic hybrids (cybrids) 
by destroying the mtDNA of SH-SY5Y neuroblastoma cells and repopulating the cells with the 
mtDNA of control or Alzheimer’s patients (75,76).   These studies observed AD-like amyloid-β 
accumulation and mitochondrial dysfunction such as reduced mitochondrial membrane potential, 
altered mitochondrial morphology and increased oxidative stress in cybrids containing AD 
mtDNA (75,76).  Chronic exposure of rodents to the complex I inhibitor rotenone mimics the 
symptoms of Parkinson’s disease (77-79).   
1.4 MITOCHONDRIA AND ALKYLATING AGENTS 
1.4.1 Alkylating agents 
There are three main categories of alkylating agents.  Nucleophilic alkylating agents are 
typically composed of a metal such as lithium or copper bound to carbons (organometallics).   
They can displace molecules such as Cl- and add themselves to electron-deficient carbons.  
Carbene alkylating agents can attack even alkane C-H bonds and are extremely reactive.   These 
two types of agents are generally used for the industrial production of polymers and will not be 
discussed further.  The third category of alkylating agent, the electrophilic alkylating agent, 
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attaches an alkyl group to nucleophiles such as the free nitrogens of nucleic acids, which can be 
mutagenic (80).  The first anti-cancer chemotherapy developed was in the form of electrophilic 
alkylating agents; these include cyclophosphamide (a nitrogen mustard), methyl 
methanesulfonate (MMS) and temozolomide (TMZ).    Electrophilic alkylating agents can block 
DNA replication and are thus toxic to rapidly dividing cells, namely cancer cells.   
Endogenous sources of alkylation include S-adenosylmethionine (SAM), which has roles 
in amino acid and polyamine biosynthesis.  SAM has been shown to methylate DNA in vitro as 
well as  proteins and lipids (81). 
1.4.2 The effects of alkylating agents on biomolecules 
1.4.2.1 Effects of alkylating agents on proteins 
 
Protein alkylation by alkylating agents has not been investigated as comprehensively as 
DNA alkylation.  In an in vitro study in 2005 with hemoglobin and the agents N-methyl-N-
nitrosourea (MNU) or MMS, the authors observed that MMS formed methylated protein adducts 
with histidine or N-terminal valine residues (80).  This preferential alkylation of histidines by 
MMS may be due to the nitrogens of histidine being stronger nucleophiles than the nitrogen of 
lysine.  In addition to histidine and valine methylation by MMS, earlier in vivo studies observed 
cysteine and histidine methylation in rodent hemoglobin by MMS (82,83).  Importantly, studies 
with glutathione (GSH) showed that MMS rapidly methylates glutathione in vitro, which 
generates the product S-methyl glutathione (84).  S-methylglutathione has a blocked –SH group 
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and unlike reduced GSH, does not aid in the reduction of oxidized peroxiredoxin (85), 
suggesting that glutathione methylation can increase oxidative stress.   
1.4.2.2 Effects of alkylating agents on nucleic acids 
MMS directly reacts with nucleophilic targets such as nucleic acids as well as amino 
acids with no metabolic activation needed (82).  Alkylating agents typically attach an alkyl group 
to guanine in DNA on N-7.  MMS methylates DNA on the N-7 or O-6 of guanine and the N-3 of 
adenine via an SN2 mechanism (reviewed in (86)).  Approximately 81% of the lesions caused by 
MMS are N7-methylguanine, which are not toxic to the cell and can be removed by BER.  Other 
measured DNA lesions include N3-methyladenine adducts, which make up 0.3% of total MMS-
induced DNA lesions and are proposed to cause stalling of replication forks (87), and O6-
methylguanine (O6-MeG), which makes up 10.4% of total MMS-induced DNA lesions and is the 
lesion responsible for the carcinogenic effect of MMS.  If the O6-methylguanine lesion is not 
removed, it can be mispaired with thymine, leading to DNA mutagenesis and/or repair by the 
mismatch repair pathway, which does not remove the O6-methylguanine but instead removes the 
thymine opposite it, leaving the possibility for another O6-MeG-T mismatch and another cycle 
of repair (reviewed in (88)). 
1.5 MTDNA REPAIR 
Until recently, it had been proposed that mitochondria only possessed a short-patch base 
excision repair (SP-BER) pathway (89).  It is now apparent that mtDNA repair occurs through 
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several pathways also existing in the nucleus; these pathways include mismatch repair (MMR), 
homologous recombination, and nonhomologous end-joining (NHEJ), as well as the key 
pathways involved in removal of oxidative and alkylation lesions, SP-BER and long-patch BER 
(LP-BER)(reviewed in (89)).   
Though mismatched bases are able to be removed in mtDNA (90), whether mitochondria 
have mismatch repair is controversial.   The presence of homologous recombination repair and 
non-homologous end-joining in mammalian mitochondria has been suggested in a couple of 
recent studies by the presence of Holliday junction-like species in human heart DNA (91) and 
end-joined products in isolated mitochondria, respectively (92).  However, these pathways have 
not been further elucidated in terms of identifying the specific proteins involved with this process 
(91-93), and it is only ligase III that has been suggested to participate in mtDNA end-joining 
(92,94).   
Base excision repair is the main pathway that removes oxidation- and alkylation-induced 
lesions in DNA.  The presence of SP-BER in the mitochondria was established in studies 
showing that uracil and other types of oxidative damage could be removed from mtDNA 
(66,95,96).  The components of mitochondrial SP-BER include lesion-specific DNA 
glycosylases, an AP endonuclease I (Ape), DNA polymerase γ (Polγ), and DNA ligase III 
(reviewed in (97)).  In mitochondrial SP-BER, a DNA glycosylase removes the damaged base to 
generate an AP site.  AP sites can also be generated via spontaneous hydrolysis of a sugar-base 
linkage.  Following the removal of the base, Ape1 cleaves the sugar-phosphate backbone 5’ to 
the AP site; this results in the production of a 3’-hydroxyl and a 5’deoxyribose-5-phosphate (5’-
dRP) residue on either side of the abasic site.  Polγ is primed by the 3’-hydroxyl residue to insert 
a nucleotide into the abasic site, followed by the Polγ-mediated removal of the 5’-dRP residue.  
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Repair is completed when DNA ligase III seals the nick in the sugar-phosphate backbone 
(reviewed in (89)).  The LP-BER pathway discovered in mitochondria also repairs oxidative base 
damage but differs from SP-BER in that the 5’-dRP flap left after Ape1 cleavage cannot be cut 
by Polγ after base insertion.   Three enzymes have been identified in mitochondria that can 
process the 5’-dRP flap; these include FEN1, EXOG, and the helicase Dna2 (98-101).   The nick 
is then sealed by DNA ligase III (reviewed in (89)).  The mtDNA repair of oxidative and 
alkylation lesions are summarized in Fig. 1. 
All of the glycosylases found in mitochondria recognize and remove oxidative mtDNA 
lesions.  Lesion-specific glycolyases identified in mitochondria include the following: OGG1, 
which removes oxidized guanines such as 8-oxoG and formamidopyrimidine (102-104); UNG1, 
which removes uracil from DNA (105); MYH, which removes adenine across from 8-oxoG 
(106,107); and the glycosylases NTH1 and NEIL1, which remove oxidized pyrimidines such as 
thymine glycols (108,109). Some of these glycosylases have redundant functions to remove base 
lesions (reviewed in (110)). The mitochondrial localization of mitochondrial DNA repair 
proteins such as UNG1 and the mitochondrial forms of OGG1, NTH1, MYH, polymerase γ and 
ligase III is due to the presence of a mitochondrial localization sequence (MLS) on these proteins 
(94,103,111-115).  An alternative splice site in the gene generates an MLS for several 
glycosylases, including the mitochondrial forms of UNG (UNG1), MYH, and OGG1 
(103,105,106).   
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Figure 1. Repair of oxidative and alkylation lesions in mtDNA 
Glycosylases involved in the removal of oxidatively-damaged mtDNA include OGG1, NEIL1, NTH1, 
UNG1, and MYH.  After removal of the damaged base to generate an AP site, APE1 prepares the site for 
POLG, which performs gap filling in the abasic site and cleaves the 5’dRP residue.  When two or more 
consecutive bases are damaged, EXOG, FEN1, and DNA2 are involved in removing the resultant 5’dRP 
flap.  The glycosylases and/or proteins involved in recognition and removal of alkylation damage in 
mtDNA are unknown. APE1 likely functions in the preparation of an AP site resulting from the removal 
of methylated bases.  POLG and Lig3 are the only known mitochondrial polymerase and DNA ligase, 
respectively, and they likely function in gap filling and ligation of the DNA strand. 
 
The removal of alkylation lesions in mtDNA is not well understood. Mammalian 
mitochondria have not been shown to possess N-methylpurine glycosylase (MPG), the 
glycosylase that recognizes alkylation lesions such as N3-methyladenine, N3-methylguanine and 
hypoxanthine, or MGMT, a direct reversal protein of alkylation lesions such as O6-
methylguanine (reviewed in (89)).  They have, however, been shown to repair alkylation lesions 
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from MMS, MNU and streptozotocin (65,116-118).  Studies in yeast indicate that MMS is 
repaired in mtDNA without a loss of mitochondrial mass or mtDNA copy number, indicating 
that MMS lesions are not being “diluted” from mtDNA (119).  Mitochondrial targeting of the 
O6-methylguanine DNA methyltransferase (MGMT) in mammalian cells increases cell survival 
after treatment with the alkylating agents MMS, TMZ, and BCNU (120,121).  In contrast, cells 
transfected with mitochondrially-targeted MPG show decreased cell survival and induction of 
apoptosis (122,123).  This is attributed to ‘imbalanced repair’ via the accumulation of cytotoxic 
BER intermediates such as single strand breaks and abasic sites (122,124,125).  Despite the 
aforementioned studies shedding light on alkylation-induced mtDNA repair, the mechanism of 
alkylation repair in mtDNA is still largely unknown. 
Two forms of human APE have been discovered, APE1, the major AP endonuclease in 
the nucleus (126), and APE2, which has weak AP endonuclease activity.  APE1 possesses an 
unconventional MLS in its C-terminus and several studies show it to localize and have activity in 
mitochondria (127-129), specifically as a 33 kDa N-terminally cleaved product in beef liver 
mitochondria (130).  A connection between oxidative stress and mitochondrial BER was 
exemplified in a study in Raji B lymphocytes showing the H2O2-dependent translocation of 
APE1 to mitochondria (131).  A 2001 study by Tsuchimoto and colleagues found a putative 
MLS in APE2, and this same study found both nuclear and mitochondrial localization of APE2 
(132). 
Two key enzymes involved in mtDNA replication and repair are DNA polymerase γ, the 
sole mitochondrial DNA polymerase, and DNA ligase III (Lig3), the source of mitochondrial 
DNA ligase activity.  It was in 1976 that DNA ligase activity in mammalian mitochondria was 
first proposed (133), but it was not until a putative mitochondrial presequence was recognized 
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within the gene for Lig3 that the source of mitochondrial ligase activity was first discovered 
(134).  It has since been established that alternate translation initiation in the Lig3 gene generates 
a nuclear form and a mitochondrial form of Lig3, the latter of which contains an MLS (94).  Lig3 
is the only DNA ligase found in mammalian mitochondria, and is the source of all mitochondrial 
DNA ligase activity during the replication and repair of mtDNA (reviewed in (89)).   
1.6 MITOPHAGY 
Defective mitochondria are potentially harmful to a cell, generating increased amounts of 
ROS, hydrolyzing ATP in an attempt to maintain a proton gradient, and releasing proapoptotic 
factors such as cytochrome c.  As with other dysfunctional and aged organelles in the cell, these 
mitochondria are eliminated by autophagy. Autophagy is a pathway in which organelles are 
enveloped by autophagosomes and are transferred to lysosomes to be degraded in response to 
nutrient deprivation or damage (reviewed in (135)).  Since the first evidence of mitochondria in 
liver autophagosomes was observed in 1962, scientists have been trying to understand the 
pathways that lead to the autophagosomal engulfment of mitochondria (136). 
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Figure 2. Mechanism of selective mitophagy 
Loss of ΔΨ precedes mitophagy but is not sufficient to cause mitophagy.  PINK1 levels are stabilized in 
response to mitochondrial dysfunction and/or loss of ΔΨ, and accumulate on the damaged mitochondria.  
Subsequent recruitment of Parkin to the damaged mitochondria is dependent on PINK1.  Parkin 
ubiquitinates mitofusins and VDAC1 on the damaged mitochondria.  After parkin accumulation on 
damaged mitochondria, the ubiquitin-binding adaptor p62 and the histone deacetylase HDAC6 
accumulate on mitochondria, but their precise role in mitophagy is not well understood.   
 
Until recently, mitochondrial autophagy was thought to occur randomly, but several 
recent studies have suggested selective mitochondrial autophagy, or mitophagy, as it was coined 
in 2005 by Dr. John Lemasters (137).  Selective mitophagy in mammalian cells is proposed to 
occur through phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and 
the E3 ubiquitin ligase parkin (reviewed in (138)).  Both PINK1 and Parkin have been shown to 
harbor mutations in autosomal recessive Parkinson’s disease, suggesting a role for mitophagy in 
neurodegeneration (reviewed in (138)).  The only recognizable domain in PINK1 is a serine-
threonine kinase domain (139).  PINK1 has an MLS and spans the outer membrane of 
mitochondria with its kinase domain facing the cytoplasm (140), but is normally very rapidly 
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degraded by proteolysis (reviewed in (138)).  However, when mitochondria are damaged, PINK1 
proteolysis is inhibited and PINK1 accumulates on the damaged mitochondria (Fig. 2)(141,142).  
Parkin is normally localized in the cytoplasm (142), but it is selectively recruited to mitochondria 
displaying dysfunction and low membrane potential (143,144).  This translocation of parkin to 
dysfunctional or uncoupled mitochondria is dependent on PINK1 (Fig. 2)(139,141-143,145).  
Increasing PINK1 expression (146,147) or increasing PINK1 accumulation on mitochondria 
(148) is sufficient to induce both the translocation of parkin and mitophagy.  Likewise, 
overexpressing parkin in heteroplasmic cybrids leads to the selective elimination of mitochondria 
with detrimental mutations in their mtDNA (144).   The interaction of PINK1 and parkin has 
been suggested to occur through direct binding (145,148,149) or PINK1-induced 
phosphorylation of parkin (146,150), but the precise mechanism by which PINK1 recruits parkin 
to mitochondria is not yet understood (reviewed in (138)).  In addition to PINK1 and parkin, the 
ubiquitin-binding adaptor p62 and the histone deacetylase HDAC6 have been suggested to 
participate in mitophagy due to their accumulation on mitochondria after parkin recruitment, but 
the role(s) and requirement of these proteins in mitophagy is controversial (Fig. 2)(reviewed in 
(138)).   
Parkin is proposed to induce mitophagy by ubiquitylating mitochondrial targets such as 
the mitofusins (151-153) and VDAC1 (145) (Fig. 2)(reviewed in (138)).  The involvement of 
mitofusin ubiquitylation in mitophagy is one of many links between mitochondrial dynamics and 
mitophagy; this will be discussed in greater detail below. 
 22 
1.7 MITOCHONDRIAL DYNAMICS 
The word “mitochondria” derives from the Greek terms for thread (mitos) and grains 
(chondros), reflecting the vast differences in mitochondrial morphology.  Mitochondrial 
morphology is fluid and is constantly being altered by the fission and fusion of mitochondria.  
The process of mitochondrial fission generates mitochondria that are more grain-like and 
fragmented, and the process of mitochondrial fusion generates an elongated, tubular network of 
mitochondria.  Proteins essential for mitochondrial fusion include the mitofusins (Mfn1 and 
Mfn2) of the outer mitochondrial membrane as well as the inner membrane protein optic atrophy 
protein 1 (OPA1) (154-156).  Critical players in mitochondrial fission include Dynamin-related 
protein 1 (Drp1) and mitochondrial fission factor (Mff)(157,158).   OPA1, Mfn1, Mfn2, and 
Drp1 are all large GTPases in the dynamin-related protein family (reviewed in (159)).  GTPase 
activity and oligomerization are essential for the activities of Mfn1, Mfn2, and Drp1 in 
mitochondrial dynamics (154,160). 
1.7.1 Mitochondrial fusion 
Mitochondrial fusion is mediated by OPA1, Mfn1, and Mfn2. Eight OPA1 isoforms of 
different lengths are generated by alternative splicing of the OPA1 gene and differential 
processing of the OPA1 protein by mitochondrial proteases (reviewed in (161)).  OPA1 is 
anchored to the IMM and faces the intermembrane space (162).  It is proposed to be responsible 
for inner membrane fusion and cristae folding by forming oligomers with other OPA1 proteins 
(162-164).  Mfn1 and Mfn2 are located in the OMM and their oligomerization with mitofusins 
on other mitochondria is suggested to allow for the OMM fusion of multiple mitochondria 
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(165,166).  In the presence of mutated OPA1 or a lack of ΔΨ, inner membrane fusion was shown 
to occur independently of outer membrane fusion (163,167).  However, it is possible that under 
normal conditions these processes are coordinated (161).   
1.7.2 Mitochondrial fission 
Drp1 is in the dynamin-related GTPase family and its homologs in yeast and mice are 
Dnm1 and Dlp1, respectively.  The mammalian Drp1 protein consists of two GTPase domains, 
one at its n-terminus and one at its c-terminus (reviewed in (161)).  The c-terminus GTPase 
domain of Drp1 functions in self-assembly (reviewed in (161)).  Drp1 is mostly cytosolic in 
mammalian cells but is able to translocate to mitochondrial tubules where it oligomerizes to 
create a “belt” around the targeted mitochondrion (157,168).  The oligomerized “belt” twists 
upon GTP cleavage in vitro, constricting the mitochondrion (168).  
Drp1 is regulated by phosphorylation, ubiquitylation, and SUMOylation (reviewed in 
(161)).  Phosphorylation of human Drp1 has been shown to occur on at least two serine residues, 
Ser618 and Ser637, which upregulate and inhibit Drp1 activity/fission, respectively (169,170).  
The dephosphorylation of Ser637 on Drp1 by calcineurin induces Drp1 translocation to 
mitochondria (171).  Ubiquitylation and SUMOylation of Drp1 have been shown to increase 
Drp1 activity/fission (reviewed in (161)).   
Drp1 was proposed to interact with a protein called Fis1 on the mitochondrial outer 
membrane (172,173).  The requirement for Fis1 in Drp1 mitochondrial localization was 
controversial, as Fis1 knockdown did not change the mitochondrial targeting of Drp1 (174).  It 
was not until 2010 that mitochondrial fission factor (Mff), a protein anchored on the OMM, was 
found to be essential for the recruitment of Drp1 to mitochondria (158).  The authors of the 2010 
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study found that (1) Drp1 and Mff physically interact in vitro and in vivo, that (2) knocking down 
Mff decreased mitochondrial fission, and (3) that overexpressing Mff stimulated Drp1 
mitochondrial targeting and fission (158).  Conversely, knocking down Fis1 did not inhibit 
fission and thus, the authors concluded that Fis1 is not necessary for mitochondrial fission (158).  
1.7.3 Mitochondrial dynamics and mitophagy 
In addition to the aforementioned parkin-mediated ubiquitylation of mitofusins, 
mitochondrial dynamics and mitophagy are interrelated. Deleting the fission gene Dynamin 1 
(DNM1), which is a homolog of the human DRP1 gene, was shown to inhibit mitophagy in yeast 
(175).  Parone and colleagues knocked down Drp1 in mammalian cells and observed a reduced 
incidence of mitochondria-LC3 colocalization, an indication of mitophagy; this suggested that 
Drp1 plays a part in autophagy in mammalian cells (176). When individual expression levels of 
mitochondrial fission and fusion components were manipulated, it was found that the pro-fusion 
protein OPA1 inhibits mitophagy and that the pro-fission proteins Fis1 and Drp1 work in 
mitophagy (177).  Fission is proposed to generate metabolically dissimilar daughter 
mitochondria; it is the membrane potential of the daughter units that determines their fate—
either to re-fuse or to be degraded by autophagy (177).  Membrane potential alone, however, is 
not the sole determinant of a mitochondrion’s fate.  In cells that are dependent on oxidative 
phosphorylation, like neurons, mitophagy does not occur when mitochondria are depolarized 
(178).   
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1.8 MAJOR HYPOTHESIS 
Previous studies have indicated a role for mtDNA damage, mtDNA loss and 
mitochondrial dysfunction in many human pathologies ranging from cancer to neurodegenerative 
diseases.  The cause, interdependency, and the kinetics of persistent mtDNA damage relative to 
mtDNA loss and mitochondrial dysfunction are not known. 
This thesis tested three major hypotheses: (1) that persistent mitochondrial DNA 
(mtDNA) damage leads to mitochondrial dysfunction through a loss in mtDNA copy number, 
and this loss is dependent on mitophagy; (2) that a compound that inhibits mitophagy, mdivi-
1, prevents mitochondrial dysfunction by preventing mtDNA loss, and (3) that general 
mitochondrial DNA ligase activity similar to Ligase III activity is essential for cell survival. 
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2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 General materials 
Pipetmen were manufactured by Gilson.  The multi-channel pipettor was manufactured 
by Socorex.  The microcentrifuge was manufactured by and purchased from Thermo Scientific.  
The centrifuge for 15 mL and 50 mL tubes was manufactured by Sorvall.  Pipette tips were 
manufactured by VWR (10 µL) and Molecular BioProducts (20, 200, 1000 µL) and purchased 
from VWR and Molecular BioProducts, respectively.  BD Falcon serological pipets, aspirating 
pipets, and tubes were purchased from BD Biosciences.  Microcentrifuge tubes were 
manufactured by Eppendorf.  The black-bottomed 96 well assay plates (Costar) used in the 
QPCR assay, Amplex Red assay and ATPlite assay were purchased from Fisher.  The plate 
reader used with the aforementioned black-bottomed plate was manufactured by and purchased 
from BioTek.   
2.1.2 Cell culture materials 
Cell lines for this work were 92TAg MEFs (a gift from Dr. Robert Sobol) and Mito-GFP 
transfected MCF7 cells. The MCF7 cells were acquired from ATCC.  DMEM high glucose and 
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Glutamax were manufactured by Gibco and purchased from Invitrogen.  RPMI 1640 (Lonza) 
was purchased from Fisher.  Fetal bovine serum (Tet system approved) was manufactured by and 
purchased from Clontech.  Penicillin/streptomycin, 1X PBS and 1X trypsin EDTA were 
manufactured by CellGro and purchased from Mediatech.   BD Falcon dishes and flasks were 
purchased from BD Biosciences.  Hydrogen peroxide was manufactured by and purchased from 
Sigma-Aldrich.  MDIVI-1 was purchased from Calbiochem.  The CASY cell counter, CASYton 
and CASYcups were manufactured by and purchased from Innovatis. 
2.1.3 QPCR materials 
The QIAcube, Qiagen Genomic-tip kit buffers G2, QBT, QC and QF and 20/G and 
100/G genomic-tips, DNeasy Blood & Tissue kit, QIAamp DNA Mini kit, Proteinase K and 
RNase A were manufactured by and purchased from Qiagen. Tris-EDTA (10 mM Tris and 1 mM 
EDTA, pH 8.0) and isopropanol was manufactured by and purchased from Fisher.  HaeII and 
PvuII restriction enzymes and related components were manufactured by and purchased from 
New England Biolabs.  Lambda (λ)/HindIII DNA (Gibco) for the DNA standard curve was 
purchased from Invitrogen.  Picogreen (Molecular Probes) was purchased from Invitrogen.  
Thermocyclers were manufactured by and purchased from Biometra.  QPCR water (Sigma) was 
purchased from Sigma.  The GeneAmp XL PCR kit and dNTPs were manufactured by and 
purchased from Applied Biosystems.  Bovine serum albumin (Roche) was purchased from 
Roche.  QPCR primers were purchased from IDT.  PCR tubes were purchased from USA 
Scientific.  Ethanol was manufactured by Pharmco-Aaper.  The PCR enclosure was 
manufactured by and purchased from Labconco.  Agarose, ethidium bromide, the horizontal gel 
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apparatus and 10X TAE were manufactured by and purchased from BioRad.  The DNA loading 
dye (GelPilot) and DNA marker (GelPilot) were purchased from Qiagen.   
2.1.4 Seahorse materials 
The Seahorse Extracellular Flux Bioanalyzer and Seahorse cartridges and plates were 
manufactured by and purchased from Seahorse Biosciences.  Oligomycin, FCCP, rotenone, 2-
deoxyglucose (2-DG), DMEM base for making unbuffered media, and dimethyl sulfoxide 
(DMSO) were purchased from Sigma.   
2.1.5 Western blot materials 
PVDF membranes were purchased from Millipore.  Nitrocellulose membranes, voltage 
packs, the vertical gel apparatus, gel transfer boxes, Bradford assay dye, BSA for protein 
standards, Laemmli sample buffer, 10X Tris-Glycine, 10X Tris-Glycine-SDS, Tween 20, 
PROTEAN TGX gels and ReadyGels (Tris-Glycine and Tris-HCl) were manufactured by and 
purchased from BioRad. NP-40 was purchased from Pierce.  Sodium vanadate (Na3VO4) was 
purchased from Sigma.  The protease inhibitor cocktail set III was purchased from Calbiochem.  
1 M Tris pH 7.4 was purchased from Sigma.  Dry milk was purchased from Santa Cruz. Protein 
marker (SeeBlue) was purchased from Invitrogen.  Porin antibody was purchased from 
Mitosciences, β-actin from Sigma, complex V α subunit antibody from Invitrogen/Mitosciences, 
Drp1 antibody from BD Biosciences, and ND4 antibody from Santa Cruz.  Mouse and rabbit 
secondary antibodies were purchased from Sigma.  The Supersignal West Femto Maximum 
Sensitivity Substrate developing kit and x-ray film was purchased from Thermo Scientific.   
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2.1.6 Amplex Red materials 
The Amplex Red Hydrogen Peroxide assay kit was manufactured by and purchased from 
Invitrogen.   
2.1.7 siRNA transfection materials 
Oligofectamine (Invitrogen) and OPTI-MEM media (Gibco) were purchased from 
Invitrogen.  siRNA constructs were purchased from Qiagen. 
2.2 CELL CULTURE 
The simian virus 40 (SV40)-transformed mouse embryonic fibroblast cell line, 92TAg, a gift 
from Dr. Robert Sobol Jr., was maintained in a 37°C incubator at 5% CO2 and grown in Dulbecco’s 
Modified Eagle Medium, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (100 units 
penicillin/100 µg streptomycin per mL), and 2% Glutamax in 100 mM dishes.  The cells were routinely 
split 2 times a week to a cell density of 1-2 x104 cells/mL.  An MCF7 luminal breast cancer cell line 
previously transfected with a Mito-GFP construct was maintained in a 37°C incubator at 5% CO2 and 
grown in RPMI supplemented with 10% FBS and 1% Penicillin/Streptomycin in 250 mL vent cap flasks.  
The cells were routinely split 2 times a week to a cell density of 4x104 cells/mL. 
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2.3 DRUG TREATMENTS 
For H2O2 treatment, 92TAg MEFs or MCF7s were plated at a density from 5-6x105 
cells/dish in duplicate 60 mm dishes for each treatment type the evening before treatment.  H2O2 
(30%, Sigma) was first diluted into serum-free media to a concentration of 0.1 M, and then 
further diluted in serum-free media to the treatment concentration (50-400 µM).  To each plate, 
6.25 mL of serum-free media +/- H2O2 was added, and then cells were incubated in the media for 
15 or 60 min at 37°C (Scheme 2, # 1 and 2).  The original plating media (conditioned media) was 
saved before the H2O2-containing media was added to the plates, kept in a 37°C water bath, and 
put back on the plates after treatment for harvest times of 1 hr, 4 hr, and 8 hr (Scheme 2, # 1 and 
2).  Cells were harvested at 0 hr (immediately following H2O2 treatment), 1 hr, 4 hr, 8 hr 
(Scheme 2, # 1 and 2).  Cells were also harvested at 1.5 hr and 24 hr for different experiments 
(not shown on Scheme 2). For harvest times of 1, 1.5, 4, 8 and 24 hours, H2O2-containing media 
was aspirated from the cells following the treatment and replaced with conditioned media 
(Scheme 2, # 1 and 2).   
For MMS treatment, 92TAg MEFs were plated at a density of 6x105 cells/dish in 
duplicate 60 mm dishes for each treatment type the evening before treatment.  MMS (Sigma) 
was diluted into serum-free media to the treatment concentration (1-3 mM).  To each plate, 6.25 
mL of serum-free media +/- MMS was added, and then cells were incubated in the media for 60 
min at 37°C (Scheme 2, # 3).  The original plating media (conditioned media) was saved before 
the MMS-containing media was added to the plates, kept in a 37°C water bath, and put back on 
the plates after treatment for harvest times of 1 hr, 4 hr, and 8 hr (Scheme 2, # 3).  Cells were 
harvested at 0 hr (immediately following MMS treatment), 8 hr, and 24 hr.  For harvest times of 
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1, 4, and 8 hrs, MMS-containing media was aspirated from the cells following the treatment and 
replaced with conditioned media.   
For mdivi-1 treatment, mdivi-1 powder had first been dissolved in DMSO at a 
concentration of 50 mM and aliquots of it were stored at -20°C.  92TAg MEFs or MCF7 cells 
were plated at a density of 6x105 cells in duplicate 60 mm dishes for each treatment type the 
evening before treatment.  To prepare for the mdivi-1 treatment of cells, the 50 mM mdivi-1 
stock was thawed and directly added to serum-free media to make a final mdivi-1 concentration 
of 10-50 µM. To each 60 mm dish, 6.25 mL of serum-free media +/- mdivi-1 was left on for 1 
hour, followed by a 1 hour treatment +/- mdivi-1 +/- 200 µM H2O2 (Scheme 2, # 4).  Cells were 
harvested immediately following treatment or 8 hours later (Scheme 2, # 4).  In some 
experiments, mdivi-1 was added to the conditioned media after the treatment at a concentration 
of 10-50 µM (Scheme 2, # 5) 
Scheme 2: Experimental design of cell treatments 
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2.4 SEAHORSE EXTRACELLULAR FLUX BIOANALYZER 
92TAg MEFs or Mito-GFP-transfected MCF7 cells were seeded in 24-well Seahorse 
tissue culture microplates in regular growth media at a density of 4x104 cells per well and 
incubated overnight at 37°C in 5% CO2.  To a separate plate containing the Seahorse cartridge, 
each well was filled with Seahorse calibrant and placed at 37°C, 0% CO2 overnight to hydrate.  
The next day, cells were inspected for confluency and treated with H2O2 as described in section 
2.3.  Before all H2O2 treatments, wells were washed with serum-free media, except for the 0-
hour recovery treatments, in which wells were washed with unbuffered media.   For 0-hour 
recovery cells, the H2O2 treatment was performed in unbuffered media at 37°C with 0% CO2.  
The cell plate was immediately loaded into the Seahorse following H2O2 treatment, with no wash 
or change of media.  For 1-hour recovery cells, the H2O2 treatment was performed in serum-free 
media at 37°C with 5% CO2, and after a wash with unbuffered media, unbuffered media was 
added to the wells for 1 hour preceding the Seahorse run and plates were put at 37°C with 0% 
CO2. For 4-hour and 8-hour recovery cells, the H2O2 treatment was performed in serum-free 
media at 37°C with 5% CO2, and after a wash with serum-free media, conditioned media was 
added back to the wells for 3 hours and 7 hours, respectively, and plates were put at 37°C with 
5% CO2.  After this incubation, wells were washed with unbuffered media and then unbuffered 
media was left on the cells for 1 hour at 37°C with 0% CO2 preceding the Seahorse run. 
In the hour immediately preceding the Seahorse run, the Seahorse cartridge was loaded 
with 75 µL of compounds dissolved in unbuffered media in the four ports per well.  Unbuffered 
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media alone was put into each of the four ports for temperature control wells and ‘blank’ wells. 
Final concentrations of compounds in the Seahorse wells are as follows: oligomycin, 1 µM; 
FCCP, 300 nM; 2-DG, 100 mM; and rotenone, 1 µM.   
The first 3-4 measurements of the Seahorse machine were used to establish a baseline 
OCR (oxygen consumption rate) and ECAR (extracellular acidification rate). Additional 
automated measurements were performed after the injection of four compounds affecting 
bioenergetic capacity: oligomycin at injection port A, FCCP at injection port B, 2-DG at 
injection port C, and rotenone at injection port D. Experiments were performed by 
simultaneously measuring OCR and ECAR rates in real time by averaging rate data for 3-6 
replicate wells for each treatment type. Data was reported in pmol/min for OCR and mpH/min 
for ECAR. After the completion of the experiment, cells were immediately trypsinized and 
counted with the CASY Cell Counter  to normalize individual well rate data to cell counts. 
2.5 DNA ISOLATION AND QUANTITATIVE PCR (QPCR) 
High molecular weight DNA was isolated either manually with the QIAGEN Genomic-
tip kit or automatically with the QIAcube instrument, the QiaAmp DNA Mini Kit and the 
appropriate animal/human protocol as described by the manufacturer.  The concentration of total 
cellular DNA was determined by PicoGreen fluorescence and was read using a plate reader with 
an excitation filer at 485 nm and an emission filter at 528 nm. λ/HindIII DNA was used as a 
standard.  When using QIAcube-extracted DNA with mitochondrial primer sets, 225 ng DNA 
was digested with HaeII restriction enzyme (for mouse) or PvuII restriction enzyme (human) for 
1 hour (for mouse) or 2 hours (human) at 37°C in a 50 µL digest mix containing 1X BSA and 20 
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units of restriction enzyme.  After the digest, PicoGreen was used to quantitate the DNA.  For 
mouse samples, 15 ng DNA for the QPCR assay was removed directly from the restriction digest 
mix.  For human samples, 7.5 ng DNA was mixed at a 1:1 ratio with 1X TE before adding to 
QPCR reaction tubes, due to an apparent inhibition of the QPCR reaction by PvuII. 
QPCRs were performed in a Biometra Professional standard thermocycler 96 with the 
GeneAmp XL PCR kit.  Reaction mixtures contained 15 ng of template DNA, 1.2 mM 
Mg(AOc)2 for use with the large mito and β-polymerase primers and 1.1 for use with the small 
mito primers, 100 ng/µ BSA (Roche, Basel, Switzerland), 0.2 mM deoxynucleotide 
triphosphates (Applied Biosystems, Foster City, CA), 20 pM primers and 1 unit of rTth DNA 
polymerase, XL (Applied Biosystems, Foster City, CA).  For human DNA, 1.1 mM Mg(AOc)2 
was used with the large mito primers and 1.2 mM Mg(AOc)2 was used with the β-polymerase 
primers and small mito primers.  For mouse, the primer nucleotide sequences were as follows: 
for the 6.6-kb fragment of the β-polymerase gene (GenBank database accession number 
AA79582), 5’-TATCTCTCTTCCTCTTCACTTCTCCCCTGG-3’and 5’-
CGTGATGCCGCCGTTGAGGGTCTCCTG-3’; for the 10-kb fragment of the mouse 
mitochondrial genome, 5’-GCCAGCCTGACCCATAGCCATAATAT-3’and 5’-GAGAG 
ATTTTATGGGTGTAATGCGG-3’, and for the 117-bp fragment of the mouse mitochondrial 
genome, 5’-CCCAGCTACTACCATCATTCAAGT-3’and 5’-
GATGGTTTGGGAGATTGGTTGATGT-3’. For human, the primer nucleotide sequences were 
as follows: for the 221-bp fragment of the human mitochondrial genome, 5’- 
CCCCACAAACCCCAT TACTAAACCCA -3’ and 5’-TTTCATCATGCGGAGATGTTGG 
ATGG-3’, for the 8.9-kb fragment of the human mitochondrial genome (GenBank database 
accession number J01415), 5’-TCTAAGCCTCCTTATTCGAGC CGA-3’ and 5’-
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TTTCATCATGCGGAGATGTTGGATGG-3’, and for the 12.2 kb region of the DNA 
polymerase β gene (GenBank database accession number L11607), 5’-CATGTCACCAC 
TGGACTCTGCAC-3’ and 5’-CCTGGAGTAGGAACAAAAATTGCTG-3’.  For the 6.6-kb and 
10-kb mouse fragments and for all the human fragments, the PCR was initiated with a 75°C hot 
start addition of the polymerase.  For the 117-bp mouse fragment, polymerase was added before 
the tubes were placed in the thermocycler.  The samples underwent thermocycler parameters as 
described in table 1 (179).   
To ensure quantitative conditions within the linear range of fragment amplification, a 
50% control containing half the concentration of template DNA was included with each sample 
set.  To ensure a lack of contamination in the PCR reaction components, a ‘no template’ control 
was included with each sample set, and contained a volume of 1X TE equal to the volume of 
DNA samples in the other reactions.  PCR products were quantified using PicoGreen 
fluorescence and a plate reader.  The fluorescence of the ‘no template’ control was subtracted 
from the average fluorescence of triplicate reads for each PCR reaction.  PCR products were run 
on an 0.8% agarose gel (for large mito and β-pol fragments) or a 1.8% agarose gel (for small 
mito fragments) to ensure correct size of the PCR product and the absence of product in the ‘no 
template’ lane.  DNA lesion frequencies were calculated relative to the control-treated samples.  
After subtracting the ‘no template’ fluorescence from the fluorescence values of the control and 
treated samples, the fluorescence values of treated samples (FT) were divided by the fluorescence 
values of control samples (FC).  The resulting ratio is the relative amplification of damaged to 
control samples.  If lesions are assumed to be randomly distributed, then nondamaged templates 
can be set as the zero class in the Poisson equation and can be used to calculate the lesion 
frequency per DNA strand of treated samples: λ = -ln FT/FC.   
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Table 1. QPCR conditions 
 
2.6 WESTERN ANALYSIS 
Cell pellets were resuspended in two volumes of NP-40 lysis buffer (1% NP-40, 10% 
glycerol, 20 mM Tris pH 7.4, 137 mM NaCl) with freshly added sodium vanadate (2 mM) and 
protease inhibitor cocktail set III (1%)  and lysed for 2 hours at 4°C on a tube rotator.  Lysates 
were centrifuged at 4°C for 15 minutes at 13000 rpm, and the supernatant was removed and put 
in a pre-chilled tube on ice.  Protein concentrations were measured using the Bradford assay 
(BioRad) and a BSA standard curve.  Samples were adjusted to the same volume and 
concentration using 1X PBS and 2X Laemmli buffer + 5% β-mercaptoethanol.  Samples of equal 
volumes and concentrations were separated by molecular weight on an SDS-PAGE 4-15% Tris-
HCl gel and transferred overnight to a 0.45 µm nitrocellulose membrane (BioRad).  Blots were 
blocked in 20% dry milk in PBST (, 1X PBS, pH 7.4, 1% Tween-20) for 2 hours at room 
temperature or overnight at 4°C depending on the affinity of the antibody.  Blots were then 
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incubated with primary antibody diluted in 10% PBST milk for 1-2 hours at room temperature or 
overnight at 4°C depending on the affinity of the antibody.  Blots were rinsed with PBST 3 times 
for 5-10 minutes each and were then incubated with peroxidase-conjugated mouse or rabbit IgG 
in 10% PBST milk for 30 minutes to 1 hour at room temperature depending on the primary 
antibody.  Blots were rinsed with PBST 3 times for 5-10 minutes each and were then developed 
using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) onto X-
ray film (Thermo Scientific) and were analyzed using ImageJ software.   
2.7 AMPLEX RED ASSAY 
Cells were plated and treated with H2O2 and/or MDIVI-1 as described in other sections.  
Amplex Red solutions (1X reaction buffer, HRP stock solution, Amplex Red solution) were 
prepared as described by the manufacturer.  At 5-10 minute increments after the H2O2 treatment 
had commenced, the plate was swirled around and a small sample of media was removed and 
placed into ice cold 1X reaction buffer.  At the end of the treatment, each sample was mixed 
briefly and pipetted into a 96-well plate, along with the standards for a H2O2 standard curve that 
had been previously prepared in reaction buffer in H2O2 concentrations ranging from 0 to 20 µM.  
Amplex Red solution was combined with 1X reaction buffer and HRP stock solution to make a 
working solution that was then pipetted into the 96-well plate.  The plate was then incubated at 
room temperature for 30 minutes, protected from light.  A plate reader with excitation in the 
range of 530-560 nM and emission at 590 nM was used to read the resulting fluorescence.  The 
H2O2 concentration of each sample was calculated using the H2O2 standard curve. 
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2.8 SIRNA-MEDIATED KNOCKDOWN OF DRP1 
MCF7 cells + Mito-GFP were plated the night before transfection in 100 mM dishes at a 
cell density of 2.5 x 105 cells per dish.  On the day of transfection, Opti-MEM and 
oligofectamine were combined in a tube and incubated at room temperature for 5 minutes.  Opti-
MEM was mixed with siRNA for either Drp1 or scrambled, combined with the 
oligofectamine/Opti-MEM, mixed and incubated at room temperature for 20 minutes.  The Drp1 
siRNA sequence is as follows: 5’-AACGCAGAGCAGCGGAAAGAG-3’, targeting amino acids 
96-116 in the human Drp1 open reading frame (180).  Before transfection, the cell plates were 
washed two times with RPMI media without FBS or antibiotics, and then 8 mL RPMI was added 
to the plates.  After the 20-minute incubation period, the Opti-MEM/siRNA/oligofectamine was 
then added dropwise to each plate and the plate was swirled.  Plates were placed at 37°C for 6 
hours.  After 6 hours, FBS was added to the plate and swirled around to mix, and then the cell 
media was removed and replaced with fresh growth media.  Three days after siRNA transfection, 
the cells were harvested for western blots or QPCR.  
2.9 TRANSMISSION ELECTRON MICROSCOPY 
92TAg MEFs were seeded in a 6-well plate at 1x105 cells per plate and incubated 
overnight at 37°C, 5% CO2.  The next day, the cells were treated for 60 minutes with 200 µM 
H2O2 and allowed to recover for 0 or 8 hours, then rinsed in PBS and fixed with 2.5% 
glutaraldehyde in PBS at room temperature for 1 hour.  Fixed cells were then washed 3 times for 
ten minutes each in PBS buffer,  then post-fixed for 1 hour at 4°C in 1% OsO4 with 1% 
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potassium ferricyanide followed by three ten-minute washes in PBS.  Cells were then dehydrated 
in a graded series of alcohol for ten minutes at each grade (30%, 50%, 70%, and 90%) with three 
15-minute changes in 100% ethanol.   This was followed by three 1 hour incubations in the 
epoxy embedding media epon.  The last change of epon was then removed and beam capsules 
full of resin were inverted over the cells and polymerized at 37°C overnight and then for 48 
hours at 60°C.  The beam capsules were then removed and the cell layers were sectioned at 70 
nm and stained with 1% uranyl acetate and 1% lead citrate. TEM images were taken of 4-6 cells 
per treatment on a JEM 1011 transmission microscope (JEOL, Peabody. MA). 
2.10 STATISTICAL ANALYSIS 
For statistical analysis of more than two samples, one-way Analysis of Variance 
(ANOVA) and Tukey test was utilized. The unpaired Student’s t test was utilized for statistical 
analysis of two samples, with a p value < 0.05 being statistically significant (*), < 0.01 very 
significant (**), and < 0.001 extremely significant (***). 
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3.0  OXIDANTS AND NOT ALKYLATING AGENTS INDUCE RAPID MTDNA 
LOSS AND MITOCHONDRIAL DYSFUNCTION 
3.1 INTRODUCTION 
Oxidative stress has been implicated in many human pathologies and involves the imbalance 
of reactive oxygen species (ROS) and cellular antioxidants.   ROS are produced by both 
exogenous and endogenous sources and include such molecules as superoxide anion (O2-•), 
hydrogen peroxide (H2O2) and the extremely reactive hydroxyl radical (OH•).  Mitochondria are 
the major source of endogenous ROS and produce as much as 90% of the cellular ROS during 
oxidative phosphorylation (reviewed in (181)). Mitochondrial DNA (mtDNA) is particularly 
susceptible to oxidative stress due to (1) its location on the inner mitochondrial membrane near 
the ROS-generating electron transport chain and (2) its lack of protective nucleosome structure; 
in fact, several studies have shown that inducing oxidative stress conditions in cells leads to 
greater levels of mtDNA damage than nuclear DNA damage (32,66,182-185).  Oxidative stress 
and mitochondrial dysfunction are implicated in premature aging (186,187), retinal degeneration 
(188), neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease (189,190), and 
various cancers (191-193)(also reviewed in (69)). 
Hydrogen peroxide is freely diffusible and widely used to induce oxidative stress in cells.  
Treatment of cells with H2O2 causes a wide range of effects based on concentration and cell type, 
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including an increase in mtDNA damage compared to nDNA damage (nuclear DNA) (32,66-
68,184), mtDNA degradation (65), increased mitochondrial mass (194), cell growth arrest 
(66,195-199), apoptosis (32,199-201), autophagy (201), increased secondary ROS such as 
superoxide (202), and decreased antioxidant activity (203,204).  The only study linking oxidative 
stress to a decrease in mitochondrial function is a 2001 study by Szweda and Nulton-Persson, 
which suggested that H2O2 treatment of isolated rat heart mitochondria caused a reversible 
decline in oxidative phosphorylation (204).   
Humans are primarily exposed to alkylating agents via cancer chemotherapy or through 
environmental sources such as tobacco smoke.  These agents add an alkyl group to modify both 
nucleic acids and proteins.  Alkylating agents such as chlorambucil and cyclophosphamide have 
been used in cancer chemotherapy (reviewed in (205)).  Endogenous sources of alkylation 
include S-adenosylmethionine (SAM), which has been shown to methylate nucleic acids, 
proteins, and lipids in vitro (81).   
Typically alkylating agents modify DNA by attaching an alkyl group to guanine in DNA on 
N-7.  MMS in particular methylates DNA on the N-7 and O6 of guanine and the N-3 of adenine.  
Although N7-methylguanine is thought to be an innocuous lesion, N3-methyladenine is toxic and 
leads to stalling of replication forks, and O6-methylguanine can lead to G-C to A-T transversions 
(206,207).  Alkylating agents such as diethylnitrosamine (DEN), dimethylnitrosamine (DMN), 
and N-methyl-N-nitrosourea (MNU) have been examined in the context of mtDNA damage and 
repair (65,116,117,208,209).  A study in 1970 by Wunderlich et al used 14C-labeled MNU to 
show that mtDNA is preferentially targeted by alkylators (208).  In addition, the authors of a 
1985 study with DEN and DEM gave mice a single dose of 14C-labeled DEN and DMN, and 
mtDNA isolated from these mice showed a 10-90-fold enrichment of 14C compared to nDNA, 
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and they also concluded that mtDNA was preferentially targeted (209). These studies may be an 
underestimate because the authors did not account for the DNA repair that may have occurred 
before the harvesting of the tissues.  It was not until 1988 that mtDNA repair of alkylating 
lesions was addressed in a study by Myers and colleagues in which the authors found that (1) O6-
MeG lesions were present at higher levels in mtDNA than in nDNA and were repaired in 
mtDNA at similar rates to nDNA, and yet (2) butyl adducts on mtDNA were repaired very 
slowly (116).  In a 1991 study, Pettepher and coworkers showed that in mammalian mtDNA, the 
alkali-labile sites produced by the alkylating agent streptozotocin were 55% repaired by 8 hours 
following treatment, and 70% repaired by 24 hours following treatment (117).  A 2009 study by 
Shokolenko and coworkers demonstrated in HeLa cells that mtDNA damage generated during a 
30 minute treatment with 1 mM MMS and 2 mM MMS is 86% repaired and 50% repaired, 
respectively, by 6 hours following treatment (65). However, the effect of this damage on 
mitochondrial function was not addressed. 
Mechanisms of protecting and maintaining mtDNA integrity include scavenging of ROS 
through antioxidants and repair of oxidative and alkyl lesions through base excision repair 
(BER)(89).  When complexes I and III generate superoxide anions during oxidative 
phosphorylation, superoxide dismutase (SOD2 A.K.A. MnSOD) converts these species to H2O2 
(210,211), which can be further reduced to water through the action of glutathione peroxidase or 
peroxiredoxins.  Once mtDNA damage has occurred, mitochondrial BER can repair oxidative 
lesions and lesions produced by alkylating agents (see (89) for review). BER enzymes are 
encoded in the nuclear DNA and must be imported into mitochondria, an action dependent upon 
the presence of a protein-encoded mitochondrial targeting sequence and the mitochondrial 
membrane potential.  However, if mtDNA damage is persistent and extensive, it has been 
 43 
suggested that mtDNA can be selectively destroyed (65,212).  This study seeks to elucidate the 
effects of the oxidant H2O2 and the alkylating agent MMS on mtDNA and mitochondrial 
function. 
3.2 RESULTS 
The goal of this study was to understand the relationship between persistent mtDNA 
damage and mitochondrial function.  To accomplish this goal, we utilized a QPCR assay to 
quantify DNA damage and mtDNA copy number in H2O2- and MMS-treated samples relative to 
control mock-treated samples, western blots to measure cellular levels of nuclear and 
mitochondrially-encoded proteins, and the Seahorse Extracellular Flux Analyzer to measure 
cellular glycolysis and oxidative phosphorylation. 
Hydrogen peroxide and MMS cause persistent mtDNA damage.  92TAg MEFs were 
incubated in H2O2-containing media for 15 minutes (Fig. 3A) or 60 minutes (Fig. 3B), with a 
wide range of H2O2 concentrations (50-400 µM for 15 minutes or 50-200 µM for 60 minutes).  
As observed previously, initial mtDNA lesions were dependent on concentration and influenced 
by the treatment time (32,66).  For example, a 15-minute treatment with 100 µM H2O2 initially 
caused 1.1 lesions/10kb, which were repaired almost completely by 8 hours (Fig. 4A).  In 
contrast, a 60 minute treatment with 100 µM H2O2 initially caused 1.6 lesions/10kb, which were 
incompletely repaired, even after 8 hours (0.65 lesions/10kb remaining)(Fig. 4A).    These data 
indicate that persistent mtDNA damage depended more upon the treatment time (15 versus 60 
minutes) than on H2O2 concentration (Fig. 4A).  To further illustrate the differences in mtDNA 
repair rates between 15- and 60-minute treated cells, the number of mtDNA lesions after a 15- or 
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60-minute treatment with 200 µM H2O2 was measured at 0, 1, 4, and 8 hours recovery (Fig. 4A). 
While the initial mtDNA lesion frequencies are comparable (Fig. 4A), the 60-minute treated cells 
show persistent mtDNA damage at 8 hours (Fig. 4B).  In regards to nDNA damage, 
amplification of a nuclear DNA fragment near the β-polymerase gene indicated that nDNA 
damage inflicted by the H2O2 treatment was below the detection range of this assay, ~1 
lesion/105 bases (data not shown).  
Once persistent mtDNA lesions had been observed in an oxidant model of damage, 
92TAg MEFs were treated with the alkylating agent MMS to determine if a non-oxidant model 
of damage would lead to mtDNA lesions persisting at 8 hours.  Based on the observation that a 
60-minute H2O2 was able to cause persistent mtDNA lesions, a 60-minute treatment time with 
MMS was employed.  After performing a dose-response experiment with MMS to establish a 
moderate initial lesion frequency (1-2 lesions/10kb mtDNA)(Fig. 5), 2 mM MMS was used to 
treat 92TAg MEFs.  A 60-minute treatment with 2 mM MMS caused 1.5/10kb initial mtDNA 
lesions, and by 8 hours following treatment, 71% of these lesions persisted (Fig. 6A).  
Additionally, this same concentration and treatment time of MMS caused 2.1/10kb nDNA 
lesions (Fig. 6B).  Unlike the mtDNA damage, nDNA damage was more effectively repaired 
(61% reduction in nDNA lesions) by 8 hours recovery.  MMS caused both persistent mtDNA 
and nDNA damage.   
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Figure 3. A 60 minute treatment with H2O2 causes persistent mtDNA damage 
Cells were plated and the following day were treated for 15 or 60 minutes with various concentrations of 
H2O2, as in Scheme 2, #1 and 2.  After the treatment, the media was replaced with conditioned media and 
the cells were allowed to recover for 0 or 8 hours.  Cells at 0 hour recovery were harvested immediately 
following treatment.  mtDNA lesions at 0 and 8 hours after a (A) 15-minute H2O2 treatment, (B) a 60-
minute H2O2 treatment at a range of concentrations. Error bars represent the SEM of n=4-19, with 2-9 
biological experiments and 2-3 replicates per treatment type.   H2O2 at 400 µM was not used to treat cells 
for 60 minutes.  One-sided ANOVA and a Tukey Test were used to analyze these data, p < 0.05 (*), < 
0.01 (**), and < 0.001 (***).  
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Figure 4. Kinetics of H2O2-induced mtDNA repair and mtDNA loss 
Cells were plated and the following day were treated for 15 or 60 minutes with H2O2 in serum-free media.  
After the treatment, the media was replaced with conditioned media and the cells were allowed to recover 
for 1, 4, or 8 hours.  Cells at 0 hr recovery were immediately harvested following H2O2 treatment.  (A) 
mtDNA lesions at various timepoints after H2O2 treatment.  Error bars represent the SEM of n=4.  (B) 
Changes in mtDNA copy number after H2O2 treatments.  Error bars represent the SEM of n=4.  A one-
sided ANOVA was used to analyze these data, p < 0.05 (*), < 0.01 (**), and < 0.001 (***).    
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Figure 5. MtDNA damage following a 60 minute treatment with 1-3 mM MMS 
Cells were plated and the following day were treated for 60 minutes with 1, 2, or 3 mM MMS in serum-
free media (Scheme 2, #3).  After the treatment, the cells were immediately harvested.  Error bars 
represent the SD of n=2, with one biological experiment and two replicates per experiment.   
 
 
Figure 6. A 60-minute treatment with MMS causes persistent mtDNA damage 
Cells were plated and the following day were treated for 60 minutes with 2 mM MMS in serum-free 
media as in Scheme 2, #3.  (A) mtDNA and (B) nDNA lesions at 0 and 8 hours after a 60-minute MMS 
treatment. Error bars represent the SEM of n=6-8, with 3 biological experiments and 2-4 replicates per 
treatment type.   One-sided ANOVA and a Tukey Test were used to analyze these data, p < 0.05 (*), < 
0.01 (**), and < 0.001 (***).   
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A rapid loss of mtDNA occurs after H2O2 treatment and not after MMS treatment.  
Treatment with 200 µM H2O2 caused a loss of mtDNA copy number in both 15- and 60-minute 
treated cells (Fig. 7A and 7B), with the 60-minute treated cells showing increased loss of 
mtDNA as compared to the 15 minute treated cells.  The rate of mtDNA loss in cells treated for 
15 or 60 minutes with 200 µM H2O2 was measured at 0, 1, 4, and 8 hours following H2O2 
treatment (Fig. 4B).  A 15-minute 200 µM H2O2 treatment caused a 29% loss of mtDNA at 8 
hours as opposed to the 65% loss of mtDNA in cells treated for 60 minutes with 200 µM H2O2, 
indicating that treatment time influences mtDNA loss more than H2O2 dose (Fig. 4B).  The initial 
mtDNA lesions of cells treated for 15 minutes with 200 µM H2O2 were similar to the initial 
mtDNA lesions of cells treated for 60 minutes with 100 µM H2O2 (Fig. 4A), but the 15-minute 
treated cells caused significantly less mtDNA loss (30% versus 52% loss) at 8 hours compared to 
the 60-minute treated cells (Fig. 4B).  These data suggest that it is the treatment duration and not 
mtDNA lesion frequency that affects loss of mtDNA.  
Although a 60-minute treatment with 2 mM MMS caused similar mtDNA lesions to a 60-
minute treatment with 100 µM H2O2 (1.4 lesions/10kb and 1.6 lesions/10kb, respectively),   the 
MMS treatment did not result in any loss of mtDNA at 8 hours following treatment (Fig. 7C).  In 
fact, there was a slight increase in the mtDNA copy number at 8 hours following MMS 
treatment.  Thus, H2O2 treatment or MMS treatment, despite causing similar lesion frequencies, 
show striking differences in loss of mtDNA. 
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Figure 7. H2O2 and not MMS causes rapid loss of mtDNA 
92TAg MEFs were treated for 15 or 60 minutes with various concentrations of H2O2 (Scheme 2, 
#1 and 2) or with 2 mM MMS as in Scheme 2, #3.  Fraction of mtDNA copy number remaining at 8 hrs 
after (A) 15-minute H2O2 treatments, (B) 60-minute H2O2 treatments or (C) 60-minute MMS treatments.  
Error bars represent the SEM of n=4-19, with 2-9 biological experiments and 2-3 replicates per treatment 
type.   H2O2 at 400 µM was not used to treat cells for 60 minutes.  There is a significant difference in the 
mtDNA copy number at 8 hours when comparing cells treated with 200 μM H2O2 for 15 minutes to cells 
treated with 200 μM H2O2 for 60 minutes. 
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A 60 minute treatment with H2O2 causes a loss of complex V α subunit.   Based on the 
persistent mtDNA lesions in the 60-minute H2O2-treated cells and in the MMS-treated cells, we 
hypothesized that there would be a decrease in a mitochondrially-encoded protein after these 
treatments.  This hypothesis was further supported by the results of a previous study that did not 
look at individual mitochondrial protein levels but showed decreased mitochondrial protein 
synthesis in epithelial cells treated with 200 µM H2O2 (67).  For this purpose, we determined the 
levels of ND4, a mitochondrially encoded subunit of complex I, normalized to the nuclear-
encoded β-actin (Fig. 8).  We found that at 8 hours after a 60-minute treatment with 200 µM 
H2O2, ND4 levels were decreased by 10% compared to control levels (Fig. 8A and 8C).  
However, at 8 hours after a 60-minute treatment with 2 mM MMS, ND4 levels were decreased 
by 35%, a significant decrease compared to control (Fig. 8B and 8C).  The 15-minute H2O2-
treated cells did not show a decrease in ND4 levels at 8 hours after treatment.   
 We measured levels of a nuclear-encoded mitochondrial protein, the α subunit of 
complex V, and also observed a significant 58% decrease compared to control in the level in 
cells treated with H2O2 for 60 minutes, but not in cells treated with MMS for 60 mins or in cells 
treated with H2O2 for 15 minutes.  The significance values compared to control are represented 
by the stars directly above the bars (Fig. 8C). 
 In addition to measuring levels of ND4 and complex V α, we measured the levels 
of the outer membrane transporter porin (VDAC-1) and found that these levels were increased at 
8 hours after 60 minute treatments with either H2O2 or MMS, but the increase in porin levels was 
not significant compared to control (Fig. 8C).   Histogram data was acquired from 2-3 biological 
repeats, with 2-3 samples per repeat, and 1-4 westerns performed for each biological repeat.  
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Included in summary figures are representative blots for the H2O2 treatment (Fig. 8A) and MMS 
treatment (Fig. 8B). 
 
 
 
Figure 8. H2O2 and MMS affect mitochondrial protein levels differently   
Cells were plated and the following day were treated for 15 or 60 minutes with 200 µM H2O2 (Scheme 2, 
#1 and 2) or for 60 minutes with 2 mM MMS (Scheme 2, #3).  Cells were harvested at 8 hr and subjected 
to western blotting. Representative blots 8 hrs after (A) H2O2 and (B) MMS treatments.  For H2O2, the 
blot is a representative of 3 experiments, with 2 separate gels per experiment and 1-3 replicates per 
treatment type.  For MMS, the blot is a representative of 2 experiments, with 1-2 gels per experiment and 
3-4 samples per treatment type. (C) Histogram of porin, ND4 and complex V α subunit levels after H2O2 
or MMS treatment, normalized to β-actin. Error bars represent standard error of the mean, n=6-10.  The 
stars directly above bars indicate a significant difference from control. 
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Hydrogen peroxide but not MMS causes a steep decline in oxidative phosphorylation and a 
concomitant increase in glycolysis. In order to examine mitochondrial function, a combination 
of four pharmacological inhibitors was used consecutively during the Seahorse extracellular flux 
analysis.  The oxygen consumption rate (OCR) measurements before compound injections are 
referred to as the basal OCR.  The first compound that is injected is oligomycin, which inhibits 
complex V in the electron transport chain and causes a decrease in respiration.  The difference 
between the resulting OCR and the basal OCR is the ATP-linked OXPHOS (Fig. 9A).  The 
second and third compounds, FCCP and 2-DG, uncouple the mitochondria and inhibit glycolysis, 
respectively, which drives mitochondrial respiration to its maximal capacity, referred to in this 
study as the total reserve capacity (Fig. 9A).  Finally, rotenone inhibits oxidative phosphorylation 
at complex I and blocks all mitochondrial oxygen consumption. 
 We predicted that persistent mtDNA damage in both 60-minute H2O2- and MMS-
treated cells would result in mitochondrial dysfunction at 8 hours.  Figure 9B shows the ATP-
linked OXPHOS at 0, 1, 4, and 8 hours following either a 15- or a 60-minute treatment with 
H2O2.  Immediately after a 60 minute treatment with hydrogen peroxide, mitochondria become 
uncoupled, as evidenced by the smaller decrease in oxygen consumption rate after the addition of 
oligomycin (Fig. 10A), and this is illustrated in Fig. 9B by the 32% drop in ATP-linked 
OXPHOS. After 1 hour recovery from H2O2 treatment (Fig. 10B), there is a decrease in ATP-
linked OXPHOS and total reserve capacity in both 15-minute and 60-minute H2O2-treated cells 
(Fig. 9B and 9C).  This effect is greater in the 60-minute treated cells (38% decrease in ATP-
linked OXPHOS and 62% decrease in total reserve capacity).  By 4 hours after the H2O2 
treatment (Fig. 10C), the 15-minute treated cells have nearly recovered their total reserve 
capacity to control levels, but their ATP-linked OXPHOS is still decreased (Fig. 9B and 9C). 
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This is in contrast to the 60-minute H2O2-treated cells, which did not recover ATP-linked 
OXPHOS or total reserve capacity to mock-treated levels (53% loss of ATP-linked OXPHOS 
and 68% loss of total reserve capacity).  At 8 hours recovery (Fig. 10D), the 15-minute H2O2-
treated cells have restored their ATP-linked OXPHOS to control levels, but the 60-minute H2O2-
treated cells now show a 51% loss of ATP-linked OXPHOS and an 87% loss of total reserve 
capacity (Fig. 9B and 9C), in addition to a 40% increase in baseline glycolysis (Fig. 9F).  The 
complete Seahorse profiles summarized in Fig. 9B and 9C are shown in Fig. 10A-D.   
 Figure 9A shows the mitochondrial pharmacologic profile of MMS- and control-
treated cells at 8 hours after treatment.  Unlike in 60-minute H2O2-treated cells, a 60 minute 
treatment with MMS did not cause massive mitochondrial dysfunction, and in fact only resulted 
in a 12% loss of ATP-linked OXPHOS (Fig. 9D) and total reserve capacity (Fig. 9E) at 8 hours 
recovery and no concomitant increase in glycolysis (Fig. 9G).   
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Figure 9. A 60-minute H2O2 treatment and not a 60-minute MMS treatment causes major 
mitochondrial dysfunction 
Cells were plated and the following day were treated for 15 or 60 minutes with 200 µM H2O2 (Scheme 2, 
#1 and 2) or for 60 minutes with 2 mM MMS (Scheme 2, #3).  ATP-linked OXPHOS is represented by 
X 1-4 - X 5-7 and total reserve capacity is represented by X 8-13 - X 5-7.  (A) Pharmacologic profile of 
mitochondrial OXPHOS 8 hours after treatment with 2 mM MMS.  Error bars represent the SEM of 2 
Seahorse experiments with 6 replicates per run.  (B) ATP-linked OXPHOS and (C) total reserve capacity 
of H2O2-treated cells at 0, 1, 4, and 8 hours as compared to control-treated cells.  (D) ATP-linked 
OXPHOS and (E) total reserve capacity of MMS-treated cells at 8 hours compared to control-treated 
cells. Basal glycolysis at 8 hours after (F) H2O2 or (G) MMS treatment compared to control-treated cells.  
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Figure 10. Time course of mitochondrial function after H2O2 treatment 
Cells were plated and the following day were treated for 15 or 60 minutes with 200 µM H2O2 (Scheme 2, 
#1 and 2).  Error bars represent the SEM of 2-3 Seahorse experiments with 6 replicates per run.  (A) 
Pharmacologic profile of mitochondrial function immediately following H2O2 treatment, or after various 
recovery times ((B): 1 hr, (C): 4 hr, and (D): 8 hr). ATP-linked OXPHOS is represented by X 1-4 - X 5-7 
and total reserve capacity is represented by X 8-13 - X 5-7.  (E) ATP-linked OXPHOS and (F) total reserve 
capacity of H2O2-treated cells as compared to control-treated cells. 
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Figure 11. Model of mtDNA damage persistence in H2O2- versus MMS-treated cells   
Mitochondrial DNA damage is predicted to persist in H2O2-treated cells due to oxidant-induced inhibition 
of mitochondrial protein import, direct oxidation of repair proteins, and/or perturbations in mitochondrial 
dynamics. MMS-induced mtDNA lesions are predicted to persist due to an insufficient alkylation repair 
pathway in mitochondria.  As of yet, no proteins that recognize and repair alkylating lesions have been 
identified in mammalian mitochondria. 
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3.3 DISCUSSION 
The purpose of this study was to better understand the relationship between persistent 
mtDNA damage and mitochondrial dysfunction.  In this study we found that: (1) mtDNA 
damage persisted in cells treated with H2O2 or MMS for 60 minutes, but not in cells treated with 
H2O2 for 15 minutes; and that H2O2 damage persistence was not dependent upon the initial lesion 
frequency; (2) both the 15 minute and 60 minute H2O2 treatments caused a significant loss of 
mtDNA, but the 60 minute treatment with MMS did not result in mtDNA loss; (3) cells treated 
for 60 minutes with MMS had significantly decreased levels of the mitochondrially-encoded 
protein ND4 (35% loss) at 8 hours, while the 60-minute H2O2-treated cells showed a decrease in 
the nuclear-encoded complex V subunit α (58% loss) at 8 hours; (4) a 60 minute H2O2 treatment 
caused a 51% loss of ATP-linked OXPHOS and a plunge in mitochondrial function to 13% of 
the control total reserve capacity by 8 hours following treatment, unlike MMS-treated cells, 
which only resulted in a 12% loss of mitochondrial function at 8 hours.   Collectively, these data 
suggest that persistent mtDNA damage is not sufficient to cause rapid mtDNA loss and 
mitochondrial dysfunction. 
QPCR analysis indicated persistent mtDNA lesions at 8 hours following a 60 minute 
treatment with H2O2 or MMS.  The persistence of the lesions is not dependent on initial lesion 
frequency but is dependent on treatment time; cells treated for 15 minutes with H2O2 did not 
have persistent mtDNA lesions at 8 hours.  Although both DNA damaging agents H2O2 and 
MMS were able to induce persistent mtDNA damage, we suggest that persistent mtDNA damage 
may occur through two different mechanisms (Fig. 11).  These differences may be due to one or 
more factors, including: (1) oxidation of mitochondrial proteins during H2O2 treatment that leads 
to a vicious cycle of ROS production and generation of mtDNA damage(32,66); (2) impaired 
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mitochondrial import of DNA repair proteins in H2O2- but not MMS-treated cells; (3) direct or 
indirect ROS-mediated inhibition of mtDNA repair during a crucial window of time for the 
initiation of repair; (4) high levels of oxidative DNA damage that does not stop the DNA 
polymerase and is therefore not detected by our assay (8-oxoG, for example); (5) insufficient 
alkylation repair pathway and/or (6) oxidant-induced alterations in mitochondrial dynamics of 
fission and fusion.   
Oxidant treatments for 15- and 60-minutes led to a loss of mtDNA at 8 hours, but a 60-
minute MMS treatment did not cause rapid mtDNA loss.  Initial mtDNA lesion frequencies for 
the H2O2 and MMS treatments were similar, and these data indicate that mtDNA loss is not 
dependent on DNA lesion frequency.  Likewise, mtDNA loss is not predictive for the persistence 
of mtDNA damage.   Our data supports earlier work, which used different methods to suggest 
that oxidatively damaged mtDNA is degraded (65,213);   in addition, it reproduces in 
mammalian cells the results of a study in yeast in which MMS treatment showed no loss of 
mtDNA (119).   
Cells treated for 60 minutes with 200 µM H2O2 showed a 10% loss in the 
mitochondrially-encoded ND4 but a 58% decrease in the nuclear-encoded complex V subunit α.  
Conversely, cells treated with MMS for 60 minutes had a 35% loss in ND4 but no significant 
decrease in complex V α (Fig. 7).  The decrease in complex V α in H2O2-treated cells could be 
due to (1) oxidant-impaired import of nuclear-encoded mitochondrial proteins (214,215) or (2) 
selective oxidative damage to the complex V subunit α gene (ATP5A1α) promoter, as suggested 
in a 2004 study (216).   
  A 60 minute H2O2 treatment led to a rapid and continual decrease in mitochondrial 
function.  ATP-linked OXPHOS showed a 32% loss immediately following treatment, which 
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increased to a 51% loss of ATP-linked OXPHOS at 8 hours recovery.  Startlingly, the initial 27% 
drop in total reserve capacity was exacerbated to 87% by 8 hours following H2O2 treatment.   In 
contrast, MMS-treated cells only showed a 12% loss of mitochondrial function by 8 hours.  
Although the H2O2 treatment and the MMS treatment both had persistent mtDNA damage at 8 
hours post-treatment, this was not sufficient to drive mitochondrial dysfunction.  The difference 
in mitochondrial function between the 60 minute H2O2 treatment and the 60 minute MMS 
treatment may instead be due to other factors, including: (1) oxidant-impaired import of nuclear-
encoded proteins, which is suggested by the 58% loss of complex V α subunit in the H2O2-
treated cells, (2) selective oxidant damage to the promoter region of ATP5A1α, which can be 
tested by PCR amplifying this region of the nuclear genome, and/or (3) the excessive H2O2-
induced loss of mtDNA (>50%), which is supported by the complete lack of OXPHOS seen in 
cells deficient in mtDNA (ρ0 cells).   
In this study we address two important questions: (1) Do persistent mtDNA lesions lead 
to rapid mtDNA loss and/or mitochondrial dysfunction?  (2) What are the effects of MMS on 
mtDNA lesion levels, mtDNA loss and mitochondrial function? The results of this study 
demonstrate that persistent mtDNA damage is not sufficient to cause rapid mtDNA loss or 
mitochondrial dysfunction.  In addition, we showed that MMS generates more nDNA lesions 
than mtDNA lesions.  Importantly, the mtDNA lesion frequencies that a range of 1-3 mM MMS 
generates are similar to H2O2-induced lesion frequencies in our study. However, unlike H2O2, 
MMS causes no DNA loss and a modest (12%) decrease in mitochondrial function.  The 
question of slow repair kinetics of MMS-induced mtDNA damage remains unresolved.  
Surprisingly little is known about the enzymology of alkylation repair in the mitochondria.  
Future studies are needed to address the mechanism and kinetics of alkylation repair in mtDNA. 
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 This study suggests that mitochondrial dysfunction is not caused by initial mtDNA 
lesion frequency or by persistent mtDNA damage and may instead be influenced by mtDNA 
copy number.  With the observation that a 15-minute 200 µM H2O2 treatment led to a 30% loss 
of mtDNA but a restoration of mitochondrial function by 8 hours, it would be predicted that a 
>50% loss of mtDNA would lead to the further decline of mitochondrial function as seen in cells 
treated with 200 µM H2O2 for 60 minutes.  Similarly, MMS-treated cells show no loss of 
mtDNA and perhaps consequently, no loss of mitochondrial function.  Future studies will 
address the cause of H2O2-induced mtDNA loss and the possible role of mitophagy and/or 
mitochondrial fission in this process. 
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4.0  MDIVI-1 PROTECTS CELLS AGAINST OXIDANT-INDUCED MTDNA 
DAMAGE INDEPENDENT OF DRP1 
4.1 INTRODUCTION 
Mitochondria are the major endogenous source and the main cellular target of reactive 
oxygen species (ROS)(217).  Hydrogen peroxide (H2O2) has been extensively used as an agent to 
induce oxidative stress in cells.  H2O2 is freely diffusible, unlike superoxide, which is the 
principal ROS produced during mitochondrial oxidative phosphorylation (OXPHOS) and cannot 
pass through membranes due to its negative charge (reviewed in (10)). H2O2 can cross the cell 
membrane and if it is not metabolized to H2O in the cytosol, it can cross nuclear and 
mitochondrial membranes because it is uncharged. Thus, the effect of ROS on nuclear DNA 
(nDNA) and mitochondrial DNA (mtDNA) can be addressed.  MtDNA is suggested to be more 
vulnerable to oxidative damage because of its proximity to superoxide production by OXPHOS 
complexes and a lack of protective histone structure.  Past studies have shown that H2O2 causes 
more mtDNA damage than nDNA damage (32,66-68,218,219), persistent mtDNA damage 
(32,66,68,219) and mtDNA loss (65,219,220).  In addition to H2O2, other oxidants such as 
menadione, an agent that generates superoxide in the cell, has been shown to induce persistent 
mtDNA damage (221) and mtDNA loss (213).   
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The observation that oxidants cause mtDNA loss led us to address the mechanism for this 
loss.  We hypothesized that mitophagy was responsible for the oxidant-induced loss of mtDNA.  
In order to test this hypothesis, we treated SV40 large T antigen-immortalized mouse embryonic 
fibroblasts (92TAg MEFs) and human breast cancer cells (MCF7 cells) with H2O2 in the 
presence or absence of the pharmacologic fission inhibitor mitochondrial division inhibitor-1 
(mdivi-1).   
Mitochondrial fission results in the fragmentation of mitochondria and it exists in a 
balance with mitochondrial fusion, a process which generates a highly-interconnected 
mitochondrial network.  Mitochondrial fission is mediated by the dynamin-related GTPase 
dynamin-related protein 1 (Drp1) and mitochondrial fission factor (Mff)(157,158,222).  When 
the expression of Drp1 or Mff is decreased, mitochondria become hyperfused (157,158,223-
225).  Mitochondrial fission and fusion have been linked to mitophagy, the selective degradation 
of mitochondria (reviewed in(161)).  Deleting Drp1 in mammalian cells or deleting Drp1’s 
homolog mitochondrial division dynamin (Dnm1) in yeast resulted in the inhibition of 
mitophagy (175-177).  Whereas fusion has been suggested to inhibit mitophagy (177), Drp1 and 
fission are proposed to promote mitophagy (175-177).   
Mdivi-1 was established as a specific inhibitor of Drp1 based on the formation of a 
highly fused mitochondrial network during mdivi-1 treatment and on the mdivi-1-mediated 
inhibition of self-assembly and GTPase activity in Dnm1, the yeast homolog of Drp1 (224).  
Since the development of mdivi-1, it has been shown to inhibit mitochondrial cytochrome c 
release during apoptosis (224), improve cell survival after ischemia/reperfusion injury in the 
heart and retina in mouse studies (226,227) and rescue mitochondrial defects induced by a 
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mutant of the mitophagy protein PINK1 (228).  These effects of mdivi-1 were purported to be 
due to the inhibition of Drp1 and thus the inhibition of fission (224,226-228). 
The purpose of this study was to determine if mitophagy is the cause of oxidant-induced 
mtDNA loss.  We predicted that the use of mdivi-1 would inhibit fission and thus, mitophagy.  
Therefore, we hypothesized that a treatment with H2O2 that normally results in a ~65% mtDNA 
loss at 8 hours in 92TAg MEFs would show no loss of mtDNA in the presence of mdivi-1.  Our 
results indicate that pretreatment of cells with mdivi-1 is protective against H2O2-induced 
mtDNA damage.  In fact, mdivi-1 reduces the amount of initial H2O2-induced mtDNA lesions 
several-fold.   Mdivi-1 also rescues cells from the H2O2-induced loss of mitochondrial function.  
Mdivi-1 completely protected against the H2O2-induced loss of mtDNA at 8 hours, but this is 
likely due to the decrease in initial mtDNA lesions and not due to manipulation of 
fission/mitophagy levels.  Mdivi-1 was not able to protect mtDNA or nDNA against lesions 
induced by the alkylating agent methyl methanesulfonate (MMS), however, which suggests a 
role for mdivi-1 in the oxidant-specific protection of mtDNA.  To ascertain that the mdivi-1-
mediated protection against H2O2-induced mtDNA was through Drp1 inhibition, Drp1 was 
knocked down ~88%; however, there was no change in the level of protection by mdivi-1 in the 
Drp1 knockdown, suggesting that mdivi-1 may be acting independently of Drp1 to protect 
mitochondria against oxidants. 
4.2 RESULTS 
The goal of this study was to determine if the oxidative stress-induced loss of mtDNA is 
due to mitochondrial fission and subsequent mitophagy.  To accomplish this goal, we utilized a 
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pharmacologic inhibitor of fission, mdivi-1.  Several endpoints were measured following 
treatment, including mtDNA damage and mtDNA copy number with QPCR, and mitochondrial 
function with the Seahorse Extracellular Flux Analyzer. 
Mdivi-1 protects 92TAg MEFs and MCF7 human cells from H2O2-induced mtDNA 
damage and from mtDNA loss when present before and during H2O2 treatment.  92TAg 
MEFs or MCF7 human breast cancer cells were incubated for 60 minutes in serum-free media 
containing 50 or 25 µM mdivi-1, respectively.  The media was removed and replaced with 
serum-free media containing 200 µM H2O2 and 25 or 50 µM mdivi-1.  For the 92TAg MEF 
treatment, 50 µM mdivi-1 was also added into the conditioned growth media during the 8 hour 
recovery.  A 1-hour pretreatment and co-treatment with 50 µM mdivi-1 reduced the initial 
mtDNA lesions in H2O2-treated 92TAg MEFs by 83%, from 3.7 lesions/10kb to 0.6 lesions/10kb 
(Fig. 12A).  Similarly, a 1-hour pretreatment and co-treatment with 25 µM mdivi-1 reduced the 
initial lesions in H2O2-treated MCF7 cells by 92%, from 0.94 lesions/10kb to 0.07 lesions/10kb 
(Fig. 12B).  By 8 hours after treatment in 92TAg MEFs, the remaining H2O2-induced lesions in 
mdivi-1-treated cells were almost completely repaired (Fig. 12A).   This was similar to H2O2-
treated MEFs, which showed almost complete repair of their mtDNA lesions at 8 hours (Fig. 
12B).  Mdivi-1 treatment alone did not cause any mtDNA lesions (Fig. 12A) or mtDNA loss 
(Fig. 12C).  Mdivi-1 completely protected 92TAg cells (Fig. 12C) and MCF7 cells (Fig. 12D) 
against the H2O2-induced 62% and 16% loss of mtDNA at 8 hours, respectively. 
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Figure 12.  Mdivi-1 protects 92TAg MEFs and MCF7 human cells from H2O2-induced mtDNA 
damage and from mtDNA loss when present before and during H2O2 treatment 
92TAg MEFs or MCF7 human breast cancer cells were treated with 50 or 25 µM mdivi-1, respectively, 
as in Scheme 2, #4.  For the 92TAg MEF treatment, 50 µM mdivi-1 was added into the media during 
recovery.  (A) MtDNA lesions and (C) mtDNA copy number in 92TAg MEFs at 0 and 8 hours following 
treatment with mdivi-1, mdivi-1/ H2O2, or H2O2. Error bars represent the SEM of n=2, with one 
experiment and 2 replicates per treatment type.  (B) MtDNA lesions and (D) mtDNA copy number in 
MCF7 cells at 0 and 8 hours following treatment with mdivi-1/ H2O2 or H2O2..  Error bars represent the 
SEM of n=4, with 2 experiments and 2 replicates per treatment type.   
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Mdivi-1 does not enhance DNA repair when added after H2O2 treatment.  Our previous 
results suggested that the presence of mdivi-1 in the recovery media was not needed for the near-
complete mtDNA repair and for the attenuation of H2O2-induced mtDNA loss at 8 hours 
following H2O2 treatment.  This led us to propose that adding mdivi-1 after treatment would not 
affect the level of H2O2-induced mtDNA lesions or mtDNA loss at 8 hours.  92TAg MEFs were 
incubated in 200 µM H2O2 in serum-free media for 60 minutes.  The media was removed and 
replaced with conditioned growth media containing 50 µM mdivi-1 for the 8 hour recovery 
timepoint.  When added after H2O2 treatment, mdivi-1 does not reduce the 2 mtDNA 
lesions/10kb remaining at 8 hours (Fig. 13A).  It is also unable to prevent the ~70% loss of 
mtDNA at 8 hours (Fig. 13B).  This is consistent with our hypothesis that mdivi-1 confers 
protection when added before and during H2O2 treatment. 
 
Figure 13.  Mdivi-1 does not enhance DNA repair when added after H2O2 treatment 
92TAg MEFs were treated with 200 µM H2O2 and 50 µM mdivi-1 for 60 minutes, as in Scheme 2, #5.  
(A) MtDNA lesions and (B) mtDNA copy number relative to control at 0 and 8 hr recovery. Error bars 
represent the SEM of n=4, with 2 experiments and 2 replicates per treatment type.  One-sided ANOVA 
and a Tukey Test were used to analyze these data, p < 0.05 (*), < 0.01 (**), and < 0.001 (***).   
 67 
Mdivi-1 protection against H2O2-induced mtDNA damage and loss is mdivi-1 dose-
dependent.  With the knowledge that 50 µM mdivi-1 was able to reduce by 6-fold the number of 
mtDNA lesions in 92TAg MEFs (Fig. 12A), we next wanted to determine if there were lower 
concentrations of mdivi-1 that could confer the same level of protection against H2O2-induced 
mtDNA damage and mtDNA loss.  Using a lower concentration of mdivi-1 could also potentially 
reduce any off-target effects of higher concentrations.  92TAg MEFs were pre- and co-treated 
with either 10, 25, or 50 µM mdivi-1 and 200 µM H2O2 and were compared with H2O2 treatment 
and control treatment.  We observed a dose-dependent increase in mtDNA lesions as the 
concentration of mdivi-1 was decreased, with 50, 25, and 10 µM mdivi-1 able to reduce the 
number of H2O2-induced lesions by 85%, 74%, and 35%, respectively (Fig. 14A).  Likewise, the 
H2O2-induced mtDNA lesions remaining at 8 hours were reduced by 95%, 86%, and 31% in 
cells pre- and co-treated with 50, 25, and 10 µM mdivi-1, respectively (Fig. 14A).   
 We next wanted to determine the lowest concentration of mdivi-1 needed for the 
complete prevention of the H2O2-induced loss of ~70% mtDNA at 8 hours.  Whereas 10 µM 
mdivi-1 was able to partially prevent the H2O2-induced loss (50% vs. 70% loss of mtDNA), it 
was 25 µM and 50 µM mdivi-1 that were able to completely prevent H2O2-induced loss (Fig. 
14B).   
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Figure 14.  Mdivi-1 protection against H2O2-induced mtDNA damage and loss is mdivi-1 dose-
dependent 
92TAg MEFs were plated and the following day were treated with 10, 25, or 50 µM mdivi-1 and 200 µM 
H2O2 as in Scheme 2, #4.   (A) MtDNA lesions at 0 and 8 hours after treatment with 10-50 µM mdivi-1 
and/or 200 µM H2O2.  (B) Change in mtDNA copy number at 0 and 8 hours following treatment with 10-
50 µM mdivi-1 and/or 200 µM H2O2.  Error bars represent the SEM of n=2, with one biological 
experiment and 2 replicates per treatment type.  One-sided ANOVA and a Tukey Test were used to 
analyze these data, p < 0.05 (*), < 0.01 (**), and < 0.001 (***).   
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Mdivi-1 does not protect against MMS-induced lesions in either mtDNA or nDNA.  The 
remarkable protection that mdivi-1 conferred against H2O2-treated cells led us to ask if the 
mdivi-1-mediated protection of mtDNA applied to other types of DNA damage.  The observation 
that 25 µM mdivi-1 was just as protective against mtDNA loss as 50 µM mdivi-1  led us to use 
25 µM mdivi-1 for this experiment.  To affirm if the mtDNA protection of mdivi-1 was a general 
phenomenon, we used the alkylating agent methyl methanesulfonate (MMS).  For this purpose, 
we performed a 1-hour pretreatment with 25 µM mdivi-1 followed by a co-treatment with 25 µM 
mdivi-1 and MMS at a concentration of 1, 2, or 3 mM and harvested cells at the 0 hour timepoint 
to determine the effect of mdivi-1 on MMS-induced lesions.  Unlike with H2O2, mdivi-1 did not 
protect against MMS-induced mtDNA lesions for any of the MMS treatments (Fig. 15A).  With 
the knowledge that mdivi-1 does not protect against initial MMS-induced mtDNA lesions, we 
next determined if mdivi-1 would protect against MMS lesions remaining at 8 hours.  We 
performed a 1-hour pretreatment with 25 µM mdivi-1 followed by a co-treatment with 25 µM 
mdivi-1 and 2 mM MMS.  Cells that were not harvested immediately following the treatment 
were put in conditioned growth media with no mdivi-1 and were allowed to recover for 8 hours.  
Not only did mdivi-1 not protect against mtDNA lesions at both 0 and 8 hours (Fig. 15B), but it 
did not confer protection against MMS-induced nDNA damage at these two timepoints (Fig. 
15C).  The effect of mdivi-1 on MMS-induced mtDNA loss could not be assessed because the 2 
mM MMS treatment that was employed did not result in any mtDNA loss at 8 hours (Fig. 15D). 
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Figure 15.  Mdivi-1 protection of DNA is not a general phenomenon – Mdivi-1 does not protect 
against MMS-induced lesions in either mtDNA or nDNA 
92TAg MEFs were plated and the following day were pretreated with 25 µM mdivi-1 followed by a 1 
hour co-treatment with 25 µM mdivi-1 and MMS at a concentration of 1, 2, or 3 mM (Scheme 2, #4).  (A) 
MtDNA lesions at 0 hours after treatment with 1-3 mM MMS and/or 25 µM mdivi-1.  (B) MtDNA 
lesions, (C) nDNA lesions, and (D) mtDNA copy number relative to control at 0 and 8 hours after 
treatment with 2 mM MMS and/or 25 µM mdivi-1.   Error bars represent the SEM of n=4, with 2 
biological experiments and 2 replicates per treatment type.  One-sided ANOVA and a Tukey Test were 
used to analyze these data, p < 0.05 (*), < 0.01 (**), and < 0.001 (***).   
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Mdivi-1 does not increase the breakdown rate of H2O2.  Our results indicated that mdivi-1 
protects against H2O2-induced mtDNA damage but not against MMS-induced mtDNA damage.  
This observation led to the hypothesis that mdivi-1 treatment enhances the breakdown rate of 
H2O2.  Similarly to the cellular antioxidant glutathione and the active site of peroxiredoxins, both 
which reduce H2O2 to water, mdivi-1 has an unblocked sulfhydryl group (224).  The Amplex 
Red assay was performed to measure the breakdown rate of H2O2 in cells treated with either 200 
µM H2O2 or concurrently with 200 µM H2O2 and 50 µM mdivi-1, and in cell-free media with the 
aforementioned treatments.  Mdivi-1 did not increase the rate of H2O2 breakdown (Fig. 16).  This 
indicates that mdivi-1 is not behaving as a general antioxidant and thus, the different effects of 
mdivi-1 on H2O2- and MMS-induced DNA damage are due to some other mechanism.  
 
Figure 16. Mdivi-1 does not increase the breakdown rate of H2O2 
 92TAg MEFs were plated and the following day were treated concurrently with 200 µM H2O2 and 50 
µM mdivi-1 for 1 hour.  Percent of initial H2O2 concentration versus time in the presence or absence of 
mdivi-1 and in the presence or absence of cells.  
 72 
 
Mdivi-1 still protects against H2O2 in Drp1 KD cells.  It has been suggested that mdivi-1 is a 
specific inhibitor of Drp1 (224).  Thus, if it is the inhibition of Drp1 that confers mdivi-1’s 
protection against H2O2-induced mtDNA damage, it would be expected that knockdown of Drp1 
would show a similar reduction of this mtDNA damage.  Drp1 knockdown could not be 
accomplished in 92TAg MEFs. Mdivi-1 was shown to behave similarly in 92TAg MEFs and 
MCF7 cells in its protection against H2O2-induced mtDNA lesions (Fig. 12B). Thus, MCF7 cells 
were transfected with Drp1 siRNA.  Three days after control or Drp1 siRNA transfection, cells 
were treated with 200 µM H2O2 or with a 25 µM mdivi-1 pre- and co-treatment with 200 µM 
H2O2.  Immediately after the treatment, cells were harvested and the mtDNA lesions (Fig. 17B) 
and mtDNA copy number (Fig. 17C) were measured.  Non-treated control siRNA and Drp1 
siRNA-transfected cells were harvested on the same day as the treated samples to determine the 
level of Drp1 knockdown (Fig. 17A).  Not only does Drp1 knockdown not behave like mdivi-1 
in protecting against H2O2-induced mtDNA lesions, but mdivi-1 still confers protection to 
mtDNA even when Drp1 levels are reduced by ~88% (Fig. 17A).  In addition, Drp1 knockdown 
cells show a 25% reduction in mtDNA copy number (Fig. 17C).  This is inconsistent with mdivi-
1 treatment, which does not show a difference in mtDNA copy number compared to control (Fig. 
12C).  These data suggest that mdivi-1’s protection against H2O2-induced mtDNA damage is 
independent of its role in inhibiting Drp1.  
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Figure 17.  Mdivi-1 still protects against H2O2-induced mtDNA damage in Drp1 KD cells 
MCF7 cells were transfected with Drp1 siRNA or control (scrambled) siRNA.  On the third day after 
transfection, cells were treated as in Scheme 2, #4 with 200 µM H2O2 and 25 µM mdivi-1.  Cells were 
harvested immediately following treatment and the (A) level of Drp1 knockdown, the (B) number of 
mtDNA lesions and (C) mtDNA copy number were measured.  Error bars represent the SEM of n=4, with 
2 biological experiments and 2 replicates per treatment type.  One-sided ANOVA and a Tukey Test were 
used to analyze these data, p < 0.05 (*), < 0.01 (**), and < 0.001 (***).   
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Mdivi-1 protects against H2O2-induced mitochondrial dysfunction in 92TAg MEFs when 
present before/during H2O2 treatment but not when added after H2O2 treatment.  With the 
observation that a 1-hour pretreatment and co-treatment with 50 µM mdivi-1 reduces H2O2-
induced mtDNA lesions by 83%, we next sought to compare the mitochondrial function of the 
mdivi-1/H2O2 treatment to the H2O2 treatment at 8 hours following treatment.  
In order to understand mitochondrial function, a combination of four pharmacological 
inhibitors was used consecutively during analysis with the Seahorse Extracellular Flux 
Bioanalyzer.  The oxygen consumption rate (OCR) measurements before compound injections 
are referred to as the basal OCR.  The first compound that is injected is oligomycin, which 
inhibits complex V in the electron transport chain and causes a decrease in respiration.  The 
difference between the resulting OCR and the basal OCR is the ATP-linked OXPHOS (Fig. 
18A).  The second and third compounds, FCCP and 2-DG, uncouple the mitochondria and 
inhibit glycolysis, respectively, which drives mitochondrial respiration to its maximal capacity, 
referred to in this study as the total reserve capacity (Fig. 18A).  Finally, rotenone inhibits 
oxidative phosphorylation at complex I and blocks all mitochondrial oxygen consumption. 
92TAg MEFs were set up at 40,000 cells/well of a Seahorse plate and were treated the 
following day.  On that day, cells were pretreated for 1 hour with either 50 µM mdivi-1 or 
serum-free media alone.  The media was removed and serum-free media containing 50 µM 
mdivi-1 and 200 µM H2O2 was added back to the cells for 1 hour.  After the treatment, 
conditioned growth media (without mdivi-1) was put back on the cells and placed in the 
incubator for 8 hours.  The pharmacologic profile of the mitochondria at 8 hours is summarized 
in terms of ATP-linked OXPHOS and total reserve capacity in Fig. 18A.  When cells were 
pretreated with mdivi-1 and co-treated with mdivi-1 during a 60 minute H2O2 treatment, the total 
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reserve capacity is two-fold higher than H2O2 alone and is comparable to the total reserve 
capacity of the control treated cells (Fig. 18A).  This indicates that a pre- and co-treatment with 
mdivi-1 protects against H2O2-induced mitochondrial dysfunction.  
Although MCF7 cells showed less initial H2O2-induced mtDNA lesions and a reduced 
loss of mtDNA compared to 92TAg MEFs (Fig. 12B and 12D), a 60-minute treatment with 200 
µM H2O2 resulted in severe mitochondrial dysfunction (Fig. 18B).  In this cell line, a 
pretreatment with 25 µM mdivi-1 and a co-treatment with 25µM mdivi-1 was not able to protect 
against H2O2-induced mitochondrial dysfunction (Fig. 18B). 
Figure 18C shows the pharmacologic profile of mitochondria in which 92TAg MEFs 
were first treated with 200 µM H2O2 for 1 hour, with 50 µM mdivi-1 present in the conditioned 
media and in the Seahorse media for the 8 hour recovery.  This treatment was already shown to 
confer no protection against mtDNA lesions and mtDNA loss at 8 hours.  As was predicted, the 
mdivi-1 post-treatment is unable to protect against H2O2-induced mitochondrial dysfunction.  
Interestingly, the presence of mdivi-1 in the Seahorse media led to low basal OXPHOS, a 90% 
loss of ATP-linked OXPHOS compared to control, and a ~40% loss of total reserve capacity 
compared to control (Fig. 18D). 
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Figure 18.  Mdivi-1 protects against H2O2-induced mitochondrial dysfunction in 92TAg   
MEFs when present before and during H2O2 treatment but not when added after H2O2 treatment 
Cells in A-C were treated as in Scheme 2, #4, with 50 µM mdivi-1 and 25 µM mdivi-1, respectively, for 
92TAg MEFs and MCF7 cells.  Histogram of mitochondrial function in (B) 92TAg MEFs and (C) MCF7 
cells. ATP-linked OXPHOS is represented by X 1-4 - X 5-7 and total reserve capacity is represented by 
X 8-13 - X 5-7.  Error bars represent the SEM of n=8-10, with 2 experiments and 4-5 replicates per 
treatment type.  (D) Pharmacologic profile of 92TAg MEFs treated as in Scheme 2 #5 with 50 µM mdivi-
1 and 200 µM H2O2 and (E) histogram of the pharmacologic profile in 18D.   
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4.3 DISCUSSION 
The purpose of this study was to use a pharmacologic inhibitor of mitochondrial fission 
(mdivi-1) to determine the role of fission and mitophagy in oxidant-induced mtDNA loss.  In this 
study we found that: (1) mdivi-1 conferred protection against H2O2-induced mtDNA damage and 
mtDNA loss in both 92TAg MEFs and MCF7 cells; (2) mdivi-1 was only able to protect against 
H2O2-induced mtDNA damage and mitochondrial dysfunction when cells were pretreated with 
mdivi-1 and co-treated with mdivi-1 and H2O2; (3) mdivi-1 pretreatment and co-treatment with 
H2O2 was able to protect against H2O2-induced mitochondrial dysfunction in 92TAg MEFs but 
not in MCF7 cells; (4) mdivi-1 did not confer protection against MMS-induced mtDNA or 
nDNA lesions; (5) mdivi-1 did not increase the breakdown rate of H2O2.  Our attempt to 
understand the mechanism of mdivi-1 protection against oxidant-induced mtDNA damage, led to 
the findings that: (1) siRNA-mediated knockdown of Drp1 did not mimic the effects of mdivi-1 
on H2O2-induced mtDNA damage; and (2) mdivi-1 still conferred protection against H2O2-
induced mtDNA damage with ~88% Drp1 knockdown.  Collectively, these data suggest that 
mdivi-1 protects against oxidant-induced mtDNA damage and mitochondrial dysfunction and 
that this protection is independent of Drp1 inhibition. 
The present study confirmed earlier findings that oxidants cause mtDNA loss (Fig. 12A 
and 12B)(65,213,219,220).  In an attempt to inhibit oxidant-induced mtDNA loss, the fission 
inhibitor mdivi-1 was employed.  Mdivi-1 has been shown to promote cell survival and normal 
mitochondrial function and inhibit apoptosis in models of ischemia/reperfusion and Parkinson’s 
disease (226-229).  The four aforementioned studies purport that the inhibition of Drp1-mediated 
mitochondrial fragmentation by mdivi-1 is the mechanism for the observed effect(s).  Most of 
these studies employed a dominant-negative Drp1 (DrpK38A) defective in GTP binding (157) to 
 78 
successfully reproduce the effects of mdivi-1 (227-229).  They did not, however, treat cells with 
mdivi-1 in the presence of Drp1 knockdown or Drp1K38A to confirm that the observed effects 
of mdivi-1 were through Drp1.   
This is the first study on the effects of mdivi-1 on mtDNA damage and mitochondrial 
function.  Once we had observed that mdivi-1 reduced initial oxidant-induced mtDNA lesions by 
83% in 92TAg MEFs (Fig. 12A), the human MCF7 breast cancer cell line was also tested, and it 
showed a similar reduction (92%) of initial mtDNA lesions by mdivi-1 (Fig. 12B).  The 
prevention of mtDNA loss by mdivi-1 at 8 hours (Fig. 12C and 12D) cannot be attributed to its 
inhibition of fission (and therefore, mitophagy), but is instead likely due to the substantial 
reduction of initial mtDNA lesions.  This is consistent with a previous study in our group 
suggesting that both initial lesions and treatment length drive mtDNA loss (219).   
The observation that mdivi-1 is only able to protect against H2O2-induced mtDNA 
damage (Fig. 12A and 12B) and mitochondrial dysfunction (Fig. 18A and 18B) when mdivi-1 is 
present before and during oxidative insult but not after oxidative insult (Fig. 13A and 18C) 
suggest that mdivi-1 is acting during this time window.  Interestingly, the pre- and co-treatment 
with mdivi-1 was able to protect against H2O2-induced mitochondrial dysfunction in 92TAg 
MEFs (Fig. 18A and 18B) but not in MCF7 cells (Fig. 18C).   
The protection of mdivi-1 against oxidant-induced mtDNA damage that was observed is 
proposed to be due to the mdivi-1-mediated (1) prevention of oxidative stress-induced 
mitochondrial fission that enhances mtDNA damage, (2) alteration of the redox environment of 
the mitochondria towards a more reducing environment before and/or during oxidant treatment, 
(3) priming of mtDNA repair, and/or (4) inhibition of oxidative phosphorylation.  
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Mdivi-1 was developed as a specific inhibitor of Drp1 and thus, we hypothesized that it 
may be protecting cells from oxidant-induced mitochondrial fission that exacerbates mtDNA 
damage.  To address this question, we knocked down Drp ~88% and treated these cells with 
mdivi-1 and H2O2 and found that mdivi-1 still protected against mtDNA lesions with the exact 
same ability as with control siRNA cells (Fig. 17A).  In addition, we observed that Drp1 KD did 
not reproduce the protective effects of mdivi-1 treatment on mtDNA (Fig. 17A).  This suggested 
that the mdivi-1 mediated protection of mtDNA against oxidant-induced damage may be 
independent of its role in inhibiting Drp1. 
A possible role for mdivi-1 in redox balance is supported by the lack of mdivi-1 
protection against alkylation-induced mtDNA or nDNA damage (Fig. 15A-C).  It is apparent 
from our Amplex Red data, however, that mdivi-1 is not directly metabolizing H2O2 (Fig. 16).  
Mdivi-1 has an unblocked sulfhydryl group (224), and thus it may be acting as a reducing agent 
to return the oxidized sulfhydryl residue in the active site of peroxiredoxins back to its reduced 
state.  Therefore, when H2O2 is added, a larger percentage of peroxiredoxins are in the reduced 
form and are thus more readily available to metabolize H2O2 to water.   
Mdivi-1 may be damaging mtDNA and thus may preemptively draw DNA repair proteins 
to the mitochondria.  This possibility will be discussed further in the conclusions and future 
directions chapter. 
The data in Fig. 18D and Fig. 18E in which the presence of mdivi-1 during the Seahorse 
run led to a basal OXPHOS level significantly below levels in control-treated cells suggests that 
mdivi-1 may be inhibiting oxidative phosphorylation.  If mdivi-1 inhibits oxidative 
phosphorylation, it may therefore inhibit a ROS-induced vicious cycle in which active OXPHOS 
leads to the exacerbation of ROS and ROS damage in mitochondria. 
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Though mdivi-1 is presumed to act solely through inhibition of the fission protein Drp1, 
our data suggest that the protection against oxidative damage to mitochondria may occur 
independently of Drp1 inhibition.  Past studies have not utilized concurrent Drp1 knockdown and 
mdivi-1 treatment to ensure that the observed effects on cell survival and apoptosis inhibition are 
derived from the same pathway (224,226-228). Thus, it is possible that the protection mdivi-1 
confers on cells after ischemia-reperfusion injury is due to a mechanism other than inhibition of 
mitochondrial fission.  Future studies are needed to identify the mechanism of mdivi-1-mediated 
protection of mtDNA against oxidant-induced damage. 
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5.0  ROLE OF MITOCHONDRIAL DNA LIGASE IN CELL SURVIVAL AND 
MITOCHONDRIAL DNA REPAIR 
5.1 INTRODUCTION 
DNA Ligase III (Lig3) is the sole mitochondrial DNA ligase in mammalian 
mitochondria, generated from an alternative translation start site in the nuclear-encoded Lig3 
gene.  The mitochondrial form of Lig3 has a mitochondrial leader sequence that enables it to 
enter the mitochondria (94).  Lig3 knockouts have been attempted, but they are embryonic lethal 
and their cells are not able to be cultured (230,231); thus, Lig3 is essential for cell viability.  This 
study helps to answer the question as to whether it is the nuclear and/or mitochondrial form of 
Lig3 that is required for cell viability, and if mitochondrially targeted DNA ligase constructs can 
maintain mitochondrial DNA (mtDNA) integrity and mtDNA copy number.   
5.2 RESULTS 
To enable complete knockdown of Lig3, a pre-emptive complementation strategy in 
mouse embryonic stem cells was developed and employed by the laboratory of Dr. Maria Jasin 
(Memorial Sloan-Kettering Cancer Center) in this study (232)(see Appendix A).  First, one allele 
of Lig3 was deleted and then cells were transfected with transgenes expressing various ligases 
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(Appendix 1, Fig. 1A).  These included the following: (1) wild-type Lig3, (2) mitochondrial- or 
(3) nuclear-targeted Lig3, (4) Ligase I (Lig1) targeted to the mitochondria, (5) a mitochondrially-
targeted minimal ligase from the chlorella virus, or Lig3 either missing (6) the domain that 
interacts with Parp1 and mitochondrial DNA (ΔZNF)(233,234) or (7) its Xrcc1-interaction 
domain (ΔBRCT)(235)(Appendix A, Figs 1A & 2A).  The Cre-Lox system was then employed 
to knock out the second allele of Lig3, producing Lig3KO/KO (Appendix A, Fig. 1A).  It was 
determined by the Dr. Jasin’s laboratory that the BRCT and ZNF domains of Lig3 are not 
essential for cell viability (Appendix A, Fig. 1B).  It was also shown by them that 
mitochondrially-targeted transgenes for Lig1, Lig3, and chlorella virus ligase could complement 
Lig3 in retaining cell viability (Appendix A, Fig. 1B & 2B).  Complementation with nuclear-
targeted Lig1 or Lig3, however, did not allow for the retention of viable cells (Appendix A, Fig. 
1B).  These data indicated that it is the mitochondrial function(s) of Lig3 that are essential for 
cell viability.  The question that I addressed in my thesis work using  a gene-specific  QPCR 
assay for DNA damage, was whether these various ligase constructs could repair oxidative 
mtDNA damage and maintain mtDNA copy number similar to Lig3KO/KO pre-emptively 
complemented with a WTLig3-GFP transgene.   
Mouse embryonic stem cells were treated with 175 µM H2O2 for 15 minutes and allowed to 
recover for 0 or 1.5 hours.  They were then harvested and the DNA was subjected to QPCR 
analysis, with endpoints of mtDNA damage and mtDNA copy number.  We found that the 
Lig3ΔBRCT, Lig3ΔZNF, and mitochondrially-targeted Lig1 and Chlorella virus ligase 
(ChVLig) could repair mtDNA damage at a similar rate to cells complemented with a wild type 
Lig3-GFP transgene (Lig3-/-, WTLig3-GFP)(Fig. 19A).  The aforementioned ligases also 
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maintained mtDNA copy number at a level similar to Lig3KO/KO cells complemented with Lig3-
GFP (Fig. 19B). 
 
      
   
Figure 19.  Cells expressing exogenous DNA ligases are competent to replicate and maintain 
mtDNA integrity 
Cells were treated with 175 µM H2O2 for 15 minutes and allowed to recover for 0 or 1.5 hours.  After the 
treatment, the cells were allowed to recover for 0 or 8 hrs.  (A) Percent mtDNA damage repaired at 1.5 
hours after treatment.  (B) mtDNA copy number compared to control (WTLig3-GFP) immediately 
following control treatment.  Error bars represent the SEM of n=2-6, with 1-3 biological experiments and 
2 replicates per treatment type.  
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5.3 DISCUSSION 
The goals of this study were to determine the following: (1) whether the nuclear and/or 
mitochondrial form of Lig3 was essential for cell viability; (2) what, if any, type of ligase 
activity could rescue cell survival in the absence of Lig3; and (3) the activities of various 
mitochondrial-targeted ligase transgenes compared to Lig3KO/KO complemented with WT Lig3-
GFP, with endpoints of mtDNA repair and maintenance of copy number.   
The results show that it is mitochondrial ligase activity that is essential for cell survival.  
Nuclear-targeted forms of Lig3 were not able to rescue cell viability in Lig3KO/KO cells, but the 
mitochondrially-targeted ligases they transfected were all able to produce viable clones.   Even 
the smallest known eukaryotic ligase (ChVLig), which consists solely of a catalytic domain 
(236), can rescue the survival of Lig3KO/KO cells; thus, the only domain of Lig3 essential to cell 
survival is the ligase catalytic core.   
Several ligase transgenes could pre-emptively complement Lig3KO/KO cells to rescue cell 
survival, including WT Lig3-GFP and mitochondrially-targeted Lig3ΔBRCT, Lig3ΔZNF, Lig1, 
and ChVLig.  These transgenic cells were then treated with H2O2 and were harvested at two 
timepoints after treatment.  We compared the mtDNA repair rates and control-treated mtDNA 
copy number of each ligase transgene to Lig3KO/KO complemented with WT Lig3-GFP to 
determine the extent of mtDNA ligase activity of each ligase.  Both the mtDNA repair ability 
and the mtDNA copy number were not significantly different than  Lig3KO/KO cells 
complemented with WT Lig3-GFP, indicating that these ligases function at a similar capacity to 
Lig3. 
In summary, these results show the necessity of Lig3 for mammalian cell survival is due 
to its mitochondrial ligase activity and not its role in the nucleus.  However, ligases such as Lig1 
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and the Chlorella viral ligase can replace Lig3 and maintain similar mitochondrial ligase 
activities as Lig3.  Thus, we propose that the necessity for mitochondrial ligase in mammalian 
cell survival allows for a simple ligase catalytic domain to fulfill the requirements for 
mitochondrial DNA ligase activity. 
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS 
In this thesis I addressed the relationship between persistent mtDNA damage, mtDNA 
loss, and mitochondrial dysfunction.  Previous studies have indicated a role for mtDNA damage, 
mtDNA loss and mitochondrial dysfunction in many human pathologies (reviewed in (8,69)).  
However, the cause and kinetics of persistent mtDNA damage, mtDNA loss and mitochondrial 
dysfunction is unknown.   
Chapter 3 tested the hypothesis that persistent mitochondrial DNA (mtDNA) damage 
leads to mitochondrial dysfunction through a loss in mtDNA copy number.  Our results show 
that persistent mtDNA damage is not sufficient to drive rapid mtDNA loss, loss of a 
mitochondrially-encoded protein or mitochondrial dysfunction.  Instead, the damage-induced 
loss of mtDNA, proteins, and mitochondrial function appears to be dependent on the type of 
DNA damage.  Treatment of cells with oxidants such as H2O2 but not the alkylating agent MMS 
leads to mtDNA loss and mitochondrial dysfunction.  Hydrogen peroxide treatment led to a 
decrease in a nuclear-encoded subunit of complex V (complex V subunit α) but not the 
mitochondrially-encoded protein ND4, whereas MMS treatment caused no decrease in complex 
V subunit α but did show a decrease in ND4.  These results indicate that the type of mtDNA 
damage sustained by the mtDNA leads to distinct outcomes.   
Mitochondria are the major producer and target of reactive oxygen species, and so they 
utilize several nuclear-encoded glycosylases to remove oxidatively-induced mtDNA lesions 
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(reviewed in (89)).  As a result, oxidant-induced lesions are repaired in mtDNA, which may 
therefore limit the effects of oxidants on the expression levels of mitochondrially-encoded 
proteins.  Conversely, how alkylation lesions are repaired in mtDNA is largely unknown. It has 
been suggested in past studies that mitochondria are able to repair simple alkylation damage to 
mtDNA (65,116-119), but the mechanism and the effects of mtDNA alkylation damage have not 
been addressed.  In this thesis, I addressed the effects of persistent mtDNA alkylation damage.  
Our results reveal that MMS-induced mtDNA damage only causes a modest (12%) loss of 
mitochondrial function and no loss of mtDNA at 8 hours in immortalized MEFs.  Our results are 
consistent with a study in yeast mitochondria, which determined that MMS generated more 
nDNA damage compared to mtDNA damage and no loss of mtDNA (119).  
MMS and H2O2 cause persistent mtDNA damage, but because of the differences in 
effects on mtDNA copy number and mitochondrial function, we propose that the persistence in 
mtDNA damage in MMS- and H2O2-treated cells may occur through two different mechanisms.  
The differences between MMS- and H2O2-induced persistent mtDNA damage may be due to one 
or more factors, including: (1) oxidation of mitochondrial proteins during H2O2 treatment that 
leads to a vicious cycle of ROS production and generation of mtDNA damage (32,66); (2) 
impaired mitochondrial import of DNA repair proteins in H2O2- but not MMS-treated cells; (3) 
direct or indirect ROS-mediated inhibition of mtDNA repair during a crucial window of time for 
the initiation of repair; (4) insufficient alkylation repair pathway and/or (5) oxidant-induced 
alterations in mitochondrial dynamics of fission and fusion.   
Cysteine and methionine are the amino acids most prone to oxidation (reviewed in (237)). 
Oxidation of the mitochondrial proteins aconitase and citrate synthase have been shown to lead 
to decreased activity of these proteins (13,58).  Oxidation of proteins can be reversible or 
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irreversible (reviewed in (237)).  Irreversibly oxidized mitochondrial proteins have been 
suggested to be degraded by the Lon protease in the mitochondrial matrix (238).  The oxidation 
of the sulfur-containing amino acids methionine and cysteine is reversible, and in fact 
mitochondria have several enzymes that reverse the oxidation of these two residues, including 
methionine sulfoxide reductase (Msr) A and B, thioredoxins, sulfiredoxins, and glutaredoxins 
(reviewed in (237)).  If protein oxidation is responsible for the persistence of H2O2-induced 
mtDNA damage, then overexpressing an oxidation reversal enzyme such as Msr A or B or the 
Lon protease should lead to less persistent mtDNA lesions at 8 hours. 
  Mitochondrial import of DNA repair proteins requires mitochondrial membrane 
potential (ΔΨ)(239,240).  Mitochondria with persistent DNA damage show a loss of ΔΨ (32). If 
impaired mitochondrial import causes H2O2-induced mtDNA lesions to persist, then dissipating 
ΔΨ with an uncoupler such as FCCP during H2O2 treatment should exacerbate the number of 
persistent mtDNA lesions at all timepoints after treatment. 
The persistence of mtDNA lesions induced by MMS is hypothesized to be due to an 
insufficient alkylation repair pathway in mitochondria.  Past studies have shown that 
mitochondria are able to repair simple alkylation damage to mtDNA (65,116-119), but the 
enzymes required for removal of alkylation lesions in mtDNA have not been identified.  The two 
major enzymes that recognize and remove alkylation damage in DNA are O6-methylguanine 
methyltransferase (MGMT) and N-methylpurine glycosylase (MPG)(reviewed in (241)).  
Although these enzymes have yet to be found in mitochondria, it is likely that one or both of 
these enzymes may remove alkylation damage in mitochondria.  If the persistence of MMS-
induced mtDNA lesions is due to insufficient alkylation repair in mtDNA, then knocking down 
MPG or MGMT should result in the exacerbation of persistent MMS-induced mtDNA lesions.  
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Additionally, it is predicted that targeting MGMT to the mitochondria would lead to a lower 
level of persistent mtDNA lesions. 
Mitochondrial fission and fusion are antagonistic and must be tightly regulated to 
maintain appropriate mitochondrial morphology and dynamics (reviewed in (161)). Oxidants 
have been proposed to induce mitochondrial fission (38).  We propose that our H2O2 treatment 
may be inducing pathological levels of fission that lead to persistent mtDNA damage and loss of 
mtDNA.  If fission is responsible for the persistence of H2O2-induced mtDNA damage, then 
either inhibiting fission proteins or overexpressing fusion proteins should lead to a decreased 
amount of persistent mtDNA lesions.  We tested this hypothesis by decreasing fission 
pharmacologically with mdivi-1, which was alleged to be a specific inhibitor of the fission 
protein Drp1 (224).  We found that mdivi-1 not only decreased the amount of persistent mtDNA 
lesions at 8 hours, but also a decreased amount of initial H2O2-induced mtDNA lesions.  These 
results are described in chapter 4 of the thesis. 
 Our data showed that H2O2 but not MMS treatment causes a decrease in mtDNA 
copy number at 8 hours after treatment.  We hypothesized that this loss of mtDNA was due to 
mitophagy, and we tested this hypothesis by using an inhibitor of fission, which is believed to 
precede mitophagy (177).  We proposed that if H2O2-induced mtDNA loss was due to 
mitophagy, then inhibiting mitochondrial fission should lead to no decrease of mtDNA copy 
number.  In addition to causing no decrease of mtDNA copy number in H2O2-treated cells, the 
pharmacologic inhibitor of fission mdivi-1 decreased initial H2O2-induced lesions by ~90%.  
This result is discussed further in chapter 4.  A more direct way to test the hypothesis that 
mitophagy is responsible for H2O2-induced mtDNA would be to knock down a mitophagy 
protein such as Beclin 1 or LC3.  If H2O2-induced mtDNA loss is due to mitophagy, then 
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knocking down a mitophagy protein should lead to no loss of mtDNA copy number after H2O2 
treatment.   
Complex V subunit α is decreased at 8 hours after H2O2 treatment but not after MMS 
treatment.  This could be due to (1) selective oxidation of the complex V subunit α (F1α1) 
promoter or (2) impaired mitochondrial import of complex V subunit α.  A 2004 study in human 
brain tissue found that F1α1 expression is decreased 2.3-fold in aged human cortexes (216).  
They attributed this decrease in F1α1 expression to selective oxidative damage to the F1α1 
promoter (216).   If the H2O2-induced loss of complex V subunit α protein is due to selective 
oxidation of its promoter, then measuring the protein levels of a nuclear-encoded mitochondrial 
protein whose gene is not known to be selectively targeted by oxidants would remove this 
variable.  For example, complex V subunit β is encoded by the nucleus and is part of the same 
moiety as subunit α of complex V (242).    Conversely, if the H2O2-induced loss of complex V 
subunit α protein is due to the compromised mitochondrial import of this protein, then 
dissipating the ΔΨ with an uncoupler such as FCCP should exacerbate the decrease in complex 
V α.   
Our results indicate a loss of ND4 at 8 hours after MMS treatment but not after H2O2 
treatment.  This may be due to the specific alkylation and degradation of the ND4 protein by 
MMS.  The effects of MMS on specific mitochondrial electron transport chain subunits are 
largely unknown.  If ND4 is selectively targeted for MMS-induced alkylation and degradation, 
then measuring the levels of another mitochondrially-encoded protein (ATPase 6, for example) 
may not show this same drop in protein level at 8 hours after MMS treatment. 
Treatment of 92TAg MEFs with H2O2 but not with MMS induces severe mitochondrial 
dysfunction at 8 hours after treatment.  This may be due to (1) the oxidation of proteins in the 
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electron transport chain (ETC) or (2) excessive mtDNA loss after H2O2 treatment.  If the 
oxidation of ETC proteins is the cause of H2O2-induced mitochondrial dysfunction, then 
overexpressing protein oxidation reversal enzymes should limit mitochondrial dysfunction at 8 
hours.  However, if excessive H2O2-induced mtDNA loss in 92TAg MEFs is responsible for the 
mitochondrial dysfunction at 8 hours, then it would be predicted that decreasing TFAM, a 
mitochondrial transcription factor that regulates mtDNA copy number (243,244), would lead to 
mitochondrial dysfunction in these cells.  The MCF7 cells showed only a modest (~16%) loss of 
mtDNA 8 hours after H2O2 treatment but showed significantly decreased OXPHOS.  This seems 
contradictory to the hypothesis that mtDNA loss drives mitochondrial dysfunction, but perhaps 
MCF7 cells depend more on their mitochondria and/or have less mitochondria than 92TAg 
MEFs.  Thus, a small decrease in mtDNA copy number may affect the mitochondrial function of 
MCF7 cells more than 92TAg MEFs. 
Our MMS study has implications in cancer chemotherapy, because alkylating agents are 
often used in the treatment of cancer.  Alkylating agents have been studied extensively in the 
context of nuclear DNA damage, and in fact, the effects of alkylating agents on nDNA are 
implicated in the cellular toxicity of these agents.  Our results show that the alkylating agent 
MMS induces persistent lesions in both nDNA and mtDNA and appears to preferentially target 
nDNA.  The lack of rapid mtDNA loss and mitochondrial dysfunction support the idea that it is 
the effects on nDNA damage that drive alkylating agent toxicity, but it cannot be ruled out that 
loss of mtDNA and mitochondrial function occur at a later timepoint.   
Chapter 5 of this thesis addresses the role of Lig3 in cell survival.  Lig3 expression had 
been shown to be essential for mammalian cell survival (230), but it was yet unknown what of 
the two form(s) of Lig3 are vital and what activity and domains of the Lig3 protein are required 
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for life.  We hypothesized that general mitochondrial DNA ligase activity is crucial for cell 
survival.  Our study established that it is the mitochondrial form of Lig3 and mitochondrial DNA 
ligase activity alone that are crucial for cell survival and mtDNA maintenance (232)(Appendix 
A).  This was exemplified by our use of a mitochondrially-targeted minimal eukaryotic Chlorella 
virus DNA ligase, which consists of a catalytic core but which was able to sustain cell survival 
and maintain mtDNA integrity and copy number in the absence of Lig3 (232).  This study 
established the importance of mtDNA maintenance in mammalian cell survival.   
Cells without mtDNA (ρ0) have been generated by either chronic treatment with ethidium 
bromide or by targeting the restriction enzyme EcoRI to mitochondria, where it then destroys all 
mtDNA (245,246).  Importantly, ρ0 cells can survive if they are supplied with pyruvate and 
uridine; they cannot perform oxidative phosphorylation but can produce ATP through glycolysis 
(245). NAD+ is normally generated by OXPHOS and is required for glycolysis (247).  Thus, in 
the absence of OXPHOS, the conversion of pyruvate to lactate enables the oxidation of NADH 
to NAD+.  Uridine is required in ρ0 media because the synthesis of thymine, cytosine, and uracil 
require uridine, a precursor of which is synthesized in active mitochondria (245,246).  Lig3 was 
found to be essential for embryonic development and cell viability (232)(Appendix A).  
However, the fact that cells can survive without mtDNA led us to ask if Lig3 knockout cells can 
survive in ρ0 media.  If Lig3 KO reproduces a ρ0 phenotype, then supplying cells with pyruvate 
and uridine should restore the cell viability of Lig3 knockout cells. 
The last hypothesis addressed in this thesis was that mdivi-1, a compound that inhibits 
mitochondrial fission, was expected to prevent H2O2-induced mitochondrial dysfunction at 8 
hours after H2O2 treatment by preventing mtDNA loss in H2O2-treated cells.   Mdivi-1 was 
employed as a method to inhibit mitophagy, based on studies suggesting that mitochondrial 
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fission promotes mitophagy (175-177).  Mdivi-1 was found to protect against initial H2O2-
induced mtDNA lesions in both 92TAg MEFs and MCF7 cells.  It was not, however, able to 
protect against MMS-induced mtDNA or nDNA lesions.  Mdivi-1 also reduced the number of 
persistent mtDNA lesions and it inhibited mtDNA loss 8 hours after H2O2 treatment in the two 
aforementioned cell types, but this inhibition of mtDNA loss was most likely due to the 
reduction in initial mtDNA lesions and not prevention of mitophagy.  When the fission protein 
Drp1, the target of mdivi-1, was knocked down ~88% in MCF7 cells, Drp1 knockdown did not 
reproduce the effects of mdivi-1.  In addition, mdivi-1 was still able to protect against H2O2-
induced mtDNA lesions in the Drp1 knockdown cells.  This suggested that mdivi-1’s protection 
against H2O2-induced mtDNA damage may be independent of Drp1.  It is possible that the 
mdivi-1-mediated inhibition of Drp1 must be within an optimal range (for example, resulting in a 
50% loss of Drp1 activity).  Therefore, excessive loss of Drp1 (~88%) would not confer 
mitochondrial protection against oxidants.  Interestingly, mdivi-1 was only able to rescue H2O2-
induced mtDNA dysfunction in 92TAg MEFs.  
Based on the data in Drp1 KD cells, mdivi-1 may be protecting against H2O2-induced 
mtDNA damage through a role independent of its role in Drp1 inhibition.  If mdivi-1 is 
protecting against H2O2-induced mtDNA damage independent of Drp1, then the next question to 
address would be how mdivi-1 is protecting mtDNA. Possible mechanisms of mdivi-1-mediated 
protection against H2O2 include the (1) preemptive reduction of oxidized peroxiredoxins, (2) 
priming of DNA repair proteins to translocate to mitochondria, (3) direct interaction with the 
hydroxyl radical, or (4) inhibition of oxidative phosphorylation. 
Oxidized peroxiredoxins utilize a second cysteine group on the enzyme to reduce the 
active site cysteine (19).  The mdivi-1 compound contains an unblocked sulfhydryl moiety (224), 
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which may directly reduce the oxidized cysteine in the peroxiredoxin active site.  This theory 
assumes that mdivi-1 is able to enter the mitochondria and to be transported to the matrix.   
Because mdivi-1 is proposed to act rapidly and reversibly (224), the Amplex Red experiment, 
which measures the rate of hydrogen peroxide breakdown, was performed using a simultaneous 
1 hour mdivi-1/H2O2 co-treatment.  This co-treatment did not show any increased rate in the 
breakdown of H2O2 in the presence of mdivi-1.  However, the experiments showing mdivi-1-
mediated protection against H2O2-induced mtDNA damage include a 1 hour mdivi-1 
pretreatment.  If a 1 hour pretreatment with mdivi-1 preemptively creates a reducing 
environment, then treating concurrently with mdivi-1 and H2O2 should decrease the protection of 
mdivi-1 against H2O2-induced mtDNA lesions.  This has been suggested in preliminary studies 
by our group (data not shown). 
 All mitochondrial DNA repair proteins are expressed from the nuclear genome.  
These DNA repair proteins contain an MLS in their sequence (115) or an MLS is generated from 
an alternative splice site of the nuclear-targeted isoform of the gene (94,103,105,106,112).   It 
was suggested in a 2006 study that the expression of nuclear-encoded mitochondrial proteins 
such as PolG and TFAM are controlled by nuclear respiratory factor (Nrf) 1 and 2, which bind to 
the promoter regions of these genes and upregulate their expression along with a coactivator such 
as PGC-1α (reviewed in (248)).  In addition to genes involved in mtDNA maintenance and 
replication, the gene expression of mtDNA repair genes may also be controlled by Nrf1 or Nrf2.  
The 1-hour pretreatment with mdivi-1 may preemptively stimulate mtDNA repair gene 
expression and translocation to mitochondria, which may act as a defensive strategy against 
H2O2.  If mdivi-1 stimulates DNA repair gene expression/mitochondrial translocation, then 
inhibiting mitochondrial protein import with an uncoupler during mdivi-1 pretreatment should 
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lead to no protection against H2O2-induced mtDNA lesions.  How mdivi-1 would promote DNA 
repair gene expression/mitochondrial translocation during the 1 hour pretreatment is suggested in 
preliminary studies to be due to the induction of mtDNA damage by mdivi-1 (data not shown). 
 The sulfhydryl moiety of mdivi-1 may enable it to directly reduce the hydroxyl 
radical and thus prevent damage to other cellular targets such as DNA and proteins.  This is 
supported by the mdivi-1-mediated decrease in H2O2-induced mtDNA damage but not MMS-
induced damage. 
 In Fig. 18D and E, the basal OXPHOS at 8 hours after a control treatment with 
mdivi-1 present in the post-treatment media is 69% decreased compared to control treatment, 
suggesting that mdivi-1 may be inhibiting OXPHOS.  In addition to the low basal OXPHOS rate 
in cells with mdivi-1 in the media, the ATP-linked OXPHOS and total reserve capacity of mdivi-
1 treated cells is 88% and 47% reduced, respectively, compared to control.  This suggests that 
mdivi-1 is inhibiting OXPHOS.  Mdivi-1-mediated OXPHOS inhibition may protect mtDNA by 
preventing a vicious cycle of ROS.   It is proposed that active OXPHOS is more heavily 
damaged by ROS than inactive OXPHOS.  Once damaged, OXPHOS itself can produce ROS, 
which exacerbates mtDNA damage. 
We found that a 1 hour pretreatment with mdivi-1 and a co-treatment with mdivi-1 and 
H2O2 was able to rescue H2O2-induced mitochondrial dysfunction in 92TAg MEFs, and yet, this 
same treatment schedule was unable to rescue H2O2-induced mitochondrial dysfunction in MCF7 
cells.  Importantly, 50 µM mdivi-1 was used for the pre- and co-treatment in the 92TAg MEFs, 
and 25 µM mdivi-1 was used for the pre- and co-treatment in the MCF7 cells.  This different 
concentration of mdivi-1 had been utilized after observing that 25 µM still protected against 
mtDNA loss in 92TAg MEFs and against ~90% of the initial H2O2-induced mtDNA damage in 
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MCF7 cells.  The difference observed in mdivi-1’s effect on mitochondrial function in 92TAg 
MEFs and MCF7 cells could be due to the lower concentration of mdivi-1 used on the MCF7 
cells (25 µM versus 50 µM) or it could be due to the specificity of mdivi-1 rescue of 
mitochondrial function in (1) fibroblasts, (2) p53-mutated/null cells, (3) mouse cells, and/or (4) 
cells with specific bioenergetics.  If mdivi-1’s rescue of H2O2-induced mitochondrial dysfunction 
is dependent upon its concentration being 50 µM, then treating MCF7 cells with 50 µM mdivi-1 
in the treatment schedule detailed above should result in rescue of H2O2-induced mitochondrial 
dysfunction in these cells.  If mdivi-1’s protection against H2O2-induced mitochondrial 
dysfunction only occurs in fibroblasts, then treating normal human dermal fibroblasts (NHDFs) 
with 50 µM mdivi-1 should result in rescue of mitochondrial function.  The treatment of NHDFs 
with mdivi-1 would also address whether p53 status or organism (mouse versus human) affects 
the rescue of mitochondrial function, because NHDFs have wild-type p53 like MCF7 cells and 
they are human cells.  If mdivi-1 is able to rescue mitochondrial function in NHDFs, then its 
protection against H2O2-induced dysfunction is not affected by p53 status or organism source. It 
would instead suggest that mdivi-1 is able to rescue mitochondrial dysfunction in fibroblasts. 
Cancer cells have been shown to have flexibility in their cellular bioenergetics (249,250).  
MCF7 cells are derived from luminal breast cancer, and thus, they may exhibit this same 
flexibility.  Our results indicated a decline in OXPHOS at 8 hours after H2O2 addition in both 
MCF7 and 92TAg MEFs.  The data indicated that at 8 hours after control treatment, the MCF7 
cells were more dependent on glycolysis than the 92TAg MEFs.  Thus, the decrease in OXPHOS 
seen at 8 hours after H2O2 addition in the MCF7 cells may be due to a different mechanism than 
the H2O2-induced in 92TAg MEFs.  We hypothesize that the decrease in OXPHOS and increase 
in ECAR response in MCF7 cells is intentionally initiated as a mechanism of coping with 
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oxidative stress (the Crabtree effect) (249), whereas the decrease in OXPHOS in 92TAg MEF 
cells occurs as a result of mitochondrial dysfunction.  MCF7 loss of mitochondrial function may 
be an intentional event after hydrogen peroxide insult. Thus, forcing the MCF7 cells to rely on 
OXPHOS with media containing galactose and pyruvate (250,251) should make the resultant 
H2O2-induced loss of OXPHOS due to mitochondrial dysfunction. Transmission electron 
microscope images were acquired from control- and H2O2-treated 92TAg MEFs, and it suggests 
that H2O2-induced mitochondrial dysfunction at 8 hours results in decreased OXPHOS in 92TAg 
MEFs (Fig. 20).  These experiments have not been repeated for MCF7 cells or in the presence of 
mdivi-1, but these would be future avenues to pursue. 
 
Figure 20.  Transmission electron images of mitochondria at 0 and 8 hours following H2O2 
treatment 
92TAg MEFs were treated for 60 minutes with H2O2 and allowed to recover for 0 or 8 hours.  A 
nontreated plate served as a control.  At the harvest timepoint, cells were fixed and processed for TEM.  
Immediately after treatment, the mitochondrial matrix and membranes are less dense, and by 8 hours, the 
mitochondria are swollen, with absent or highly disorganized cristae, and the mitochondrial matrix and 
membranes are less dense than the 0 hour recovery cells. 
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This work demonstrates that persistent damage induced by oxidants and alkylating agents 
leads to divergent downstream events such as loss of mtDNA and mitochondrial dysfunction 
after oxidant treatment and no significant effect on mtDNA loss or function after treatment with 
MMS.  The fission inhibitor mdivi-1 is able to protect against oxidant-induced effects on 
mtDNA and function but is unable to protect against MMS-induced mtDNA damage.  Although 
we show that the maintenance of mtDNA copy number and mtDNA integrity is essential for cell 
survival, oxidants and alkylating agents affect mitochondria differently.  These differences 
between oxidative mtDNA damage and alkylation mtDNA damage are exploited by mdivi-1. 
The mechanism for mdivi-1 action on oxidative mtDNA damage appears to be a role 
independent of its role in inhibiting mitochondrial fission.  
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Crucial role forDNA ligase III inmitochondria butnot
in Xrcc1-dependent repair
Deniz Simsek1,2, Amy Furda3, Yankun Gao4, Je´roˆme Artus1, Erika Brunet1,5,6,7, Anna-Katerina Hadjantonakis1,2, Bennett Van
Houten3, Stewart Shuman2,8, Peter J. McKinnon4 & Maria Jasin1,2
Mammalian cells have three ATP-dependent DNA ligases, which
are required for DNA replication and repair1. Homologues of
ligase I (Lig1) and ligase IV (Lig4) are ubiquitous in Eukarya,
whereas ligase III (Lig3), which has nuclear and mitochondrial
forms, appears to be restricted to vertebrates. Lig3 is implicated
in various DNA repair pathways with its partner protein Xrcc1
(ref. 1). Deletion of Lig3 results in early embryonic lethality in
mice, as well as apparent cellular lethality2, which has precluded
definitive characterization of Lig3 function. Here we used pre-
emptive complementation to determine the viability requirement
for Lig3 in mammalian cells and its requirement in DNA repair.
Various forms of Lig3 were introduced stably into mouse embry-
onic stem (mES) cells containing a conditional allele of Lig3 that
could be deleted with Cre recombinase. With this approach, we find
that the mitochondrial, but not nuclear, Lig3 is required for cellular
viability. Although the catalytic function of Lig3 is required, the zinc
finger (ZnF) and BRCA1 carboxy (C)-terminal-related (BRCT)
domains of Lig3 are not. Remarkably, the viability requirement
for Lig3 can be circumvented by targeting Lig1 to the mitochondria
or expressing Chlorella virus DNA ligase, the minimal eukaryal
nick-sealing enzyme3, or Escherichia coli LigA, anNAD1-dependent
ligase1. Lig3-null cells are not sensitive to several DNA-damaging
agents that sensitize Xrcc1-deficient cells4–6. Our results establish a
role for Lig3 inmitochondria, but distinguish it from its interacting
protein Xrcc1.
Biochemical and cell biological experiments implicate the nuclear
Lig3–Xrcc1 complex in single-strand break repair, short patch base
excision repair and nucleotide excision repair1. Lig3 and Xrcc1 interact
through carboxy (C)-terminal BRCT domains found in each protein7.
This interaction is important for the stability of Lig3 (ref. 7) and the
recruitment of Lig3 to DNA damage foci8. Purified Lig3–Xrcc1 is pro-
ficient at nick sealing in vitro9, and the complex associates with several
other proteins involved in single-strand break repair, including Parp1
(ref. 10), aprataxin and TDP1 (ref. 1).
Lig3 also has a mitochondrial form due to an alternative translation
start site, which results in a mitochondrial leader sequence (MLS)11.
Mammals differ in this respect from budding yeast, where the Lig1
homologue, Cdc9, is the mitochondrial DNA ligase12. In mitochon-
dria, Lig3 appears to act independently of Xrcc1, as Xrcc1 is not pre-
sent in this organelle13. Disruption of the Lig3 gene, like Xrcc1, results
in early embryonic lethality in the mouse2,5, and Lig3-null cell lines
could not be established from these animals2. The similar timing of
lethality of Lig3 and Xrcc1-null embryos suggests that death could
result from similar phenotypic consequences related to Lig3 nuclear
functions in DNA repair. Alternatively, or in addition, the mitochon-
drial function of Lig3 may be critical for survival.
To determine whether Lig3 is an essential gene because of its
nuclear and/or mitochondrial function, we developed a pre-emptive
complementation strategy in mES cells (Fig. 1a). A Lig3KO/cKOneo1 cell
linewas constructedwhich contains one conditionalLig3 allelewith an
intronic Neo selection marker and LoxP sites flanking exons 6 and 14
and a second allele in which these exons were already removed by Cre
recombinase (Fig. 1a and Supplementary Fig. 1). These exons encode
part of the DNA binding domain and the catalytic core of the protein.
Cre recombinase was expressed in the Lig3KO/cKOneo1 cells, and 145
clones were replica-plated in media with or without G418. No G418-
sensitive clones (that is, Lig3KO/KO) were obtained (Fig. 1b), consistent
with the requirement for Lig3 for cellular viability. We then stably
integrated transgenes expressing wild-type (WT), mitochondrial or
nuclear Lig3; the nuclear (NucLig3) version lacked the MLS, and the
mitochondrial (MtLig3) version contained the MLS but was mutated
at the nuclear translation initiation site (M88T) (Fig. 1c and Sup-
plementary Fig. 2). Green fluorescent protein (GFP) fusions of these
proteins were also tested (Supplementary Fig. 3a).
To determine which Lig3 transgenes allow the survival of cells
deleted for endogenous Lig3, Cre recombinase was used to transform
Lig3KO/cKOneo1 cells to Lig3KO/KO cells. A large fraction of the post-Cre
clones expressing WT Lig3 or MtLig3 were G418 sensitive (34–50%),
whereas noG418-sensitive clones were obtainedwithNucLig3 (Fig. 1b
and Supplementary Fig. 4). We confirmed that G418-sensitive cells
were Lig3KO/KO (Fig. 1a) and that endogenous Lig3 was no longer
present, with the only Lig3 present in the cells expressed from the
transgene (Fig. 1d). Thus, cellular viability requires mitochondrial
Lig3. To determine whether DNA ligase activity was essential for cell
survival, we introduced a K508V mutation that abolishes ligase
adenylylation and nick-sealing1 intoMtLig3.NoG418-sensitive clones
were derived from four independent transgenic cell lines (Fig. 1b),
demonstrating that the requirement for mitochondrial Lig3 depends
on its ligase activity.
BRCT domains are frequently involved in protein–protein interac-
tions, and the BRCT domain of Lig3 is known to interact with Xrcc1
(ref. 7). However, as Xrcc1 is not found in mitochondria13, the role of
the BRCT domain for mitochondrial function of Lig3 is uncertain.
Loss of the BRCT domain had no effect on the presence of Lig3 in
mitochondria (Lig3-DBRCT andMtLig3-DBRCT; Supplementary Fig.
3a and data not shown). Lig3KO/KO clones expressing Lig3-DBRCT or
MtLig3-DBRCT (Fig. 2a) were recovered as a substantial fraction of
clones (39–49%; Fig. 2b), indicating that the BRCT domain is not
required for viability. Thus, MtLig3 does not have a partner protein
bound to its BRCT domain that is essential for its function.
A unique feature of Lig3 comparedwith the othermammalianDNA
ligases is a ZnF at its amino (N) terminus. The Lig3 ZnF interacts with
Parp1 (ref. 10), and this interaction is reported to be important for the
association of Lig3 with mitochondrial DNA (mtDNA)14. Biochemical
studies have shown that the ZnF promotesDNAnick recognition15 and
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intermolecular ligation16. Nonetheless, Lig3KO/KO clones expressing
Lig3-DZnF or MtLig3-DZnF (Fig. 2a) were efficiently recovered after
Cre expression (37–38%; Fig. 2b).
Our results reveal that the catalytic activity of Lig3 is critical for cell
survival, but that the ZnF and BRCT domains, which interact with
various proteins, are dispensable, raising the question whether Lig3
itself is critical for mitochondrial function, or whether another DNA
ligase would substitute. As the Lig1 homologue in yeast provides
mitochondrial ligase function12, we provided an MLS to murine Lig1
(Fig. 2a). GFP-taggedMtLig1, but notWT Lig1, was localized to mito-
chondria (Supplementary Fig. 3c), as expected. Stable Lig3KO/cKOneo1
cell lines expressing MtLig1, but not WT Lig1, could be efficiently
converted to Lig3KO/KO (35%; Fig. 2b). MtLig1 Lig3KO/KO clones were
devoid of Lig3, and expressed instead a larger Lig1 protein due to the
GFP tag (Fig. 3a). Thus, targeting Lig1 to mitochondria circumvents
the viability requirement for Lig3, allowing the creation of Lig3-null
cells. In this way, the DNA ligase repertoire of mammalian cells is
converted to that of yeast.
Given that ZnF and BRCT-truncated forms of Lig3 and MtLig1
could rescue Lig3KO/KO cells, we investigated their proficiency in
mtDNA maintenance and repair. The mtDNA copy number was
maintained as well (or better) in these cell lines than in WT Lig3-
expressing cells (Fig. 2c), indicating that cells expressing these altered
ligases are competent to replicate their mtDNA during continued
passage.A long-range quantitative PCR (qPCR) assay17 was performed
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to assess the mitochondrial base excision repair capacity of these cells
in response to oxidative damage, and these altered ligases were
similarly proficient in repairing mtDNA lesions compared with WT
Lig3-expressing cells (Fig. 2d).
At 298 amino acids, Chlorella virus DNA ligase (ChVLig) is the
smallest eukaryal ligase known, consisting solely of a catalytic core3.
We expressed ChVLig and a modified form containing an MLS,
MtChVLig (Fig. 2a), and found that expression of either allowed dele-
tion of Lig3 from the mouse genome (Fig. 2b). It is conceivable that
ChVLig contains an internal sequence that allows translocation into
mitochondria18. Thus, a minimal ATP-dependent ligase, devoid of
auxiliary domains, rescues the survival of Lig3-null mammalian cells.
Further, Lig3-null cells rescued by MtChVLig were proficient at
mtDNA maintenance (Fig. 2c) and repair (Fig. 2d).
Whereas ATP-dependent ligases are widespread, ligases that use
NAD1 as a cofactor are usually restricted to bacteria1. E. coli DNA
ligase, LigA, is NAD1 dependent and has a distinctive domain organ-
ization compared withmammalian ligases1. LigA and amodified form
with an MLS (Fig. 2a) were expressed from transgenes, and like
ChVLig, both forms were found to allow the survival of Lig3-null cells
(Fig. 2b). Hence, there is no essential functional distinction between
NAD1 and ATP-dependent ligases in the mammalian mitochondria,
akin to swaps of NAD1 and ATP-dependent ligases performed in
bacteria19 and yeast20.
We demonstrated that nuclear Lig3 is not required for cell survival,
as MtLig1 Lig3KO/KO cells are null for Lig3. To impair nuclear locali-
zation of MtLig1, we removed the Lig1 nuclear localization signal,
creating MtLig1-DNLS Lig3KO/KO cells (Fig. 2a, b and Supplementary
Fig. 3c). MtLig1-DNLS, like MtLig1, was expressed at a substantially
lower level than endogenous Lig1 (Fig. 3a). As a complementary
approach, we also created Lig3KO/KO cells expressing MtLig3-
DBRCT-NES, whose interaction with Xrcc1 is abrogated and which
is excluded from the nucleus by addition of a potent nuclear export
signal (NES)21 (Figs 2a, b and 3a and Supplementary Fig. 3b).
To assess the nuclear role of Lig3, we tested the sensitivity of Lig3-
null (Lig3KO/KO;MtLig1-DNLS) and nuclear Lig3-deficient (Lig3KO/KO;
MtLig3-DBRCT-NES) cells to a variety of DNA-damaging agents.
Xrcc1-deficient cells are highly sensitive to alkylating agents like
methyl methanesulphonate4–6. If the interaction of Xrcc1 with Lig3 is
relevant to base excision repair, cells without nuclear Lig3 would also
be expected to be sensitive tomethylmethanesulphonate; however, we
found that these cells were no more sensitive than transgenic cells
expressing WT Lig3 (Fig. 3b) or the parental cells (Supplementary
Fig. 5). Xrcc1-deficient cells are also sensitive to agents that produce
DNA single- and double-strand breaks, including hydrogen peroxide
and ionizing radiation4–6, and to ultraviolet radiation22. By contrast, we
found that cells without nuclear Lig3 were not any more sensitive to
these agents than control cells (Fig. 3c–e and Supplementary Fig. 5).
Thus, Lig3 appears to be dispensable for nuclear DNA damage repair
that requires Xrcc1. Finally, we tested sensitivity to Parp inhibition,
which causes the accumulation of single-strand breaks23, and found
that nuclear Lig3 was also not required for resistance of cells to Parp
inhibition (Fig. 3f).
As the ZnF domain of Lig3 has been reported to be critical for its
intermolecular ligation activity16, we also investigatedwhether deletion
of this domain in the context of an otherwise WT Lig3 would impair
resistance of cells to ionizing radiation. As with the other mutants,
Lig3-DZnF Lig3KO/KO cells were no more sensitive than control cells
(Fig. 3e).
Xrcc1-deficient cells are notable for their high rate of spontaneous
sister-chromatid exchange (SCE): both mouse and hamster Xrcc1
mutants have approximately tenfold higher SCE levels than control
cells4,5. We examined spontaneous SCEs in MtLig1 Lig3KO/KO cells and
found levels similar to control cells (Fig. 3g). Thus, the high level of SCEs
found with Xrcc1 deficiency is not recapitulated with Lig3 deficiency.
The lack of Lig3 in many model organisms has limited their use to
study its function. Inmouse, disruption of any of the DNA ligase genes
leads to embryonic death, but the most severe phenotype occurs with
Lig3 disruption2,24,25. Lig1 has been considered to be the replicative
ligase1,26, but the earlier death associatedwith Lig3 disruption, together
with the inability to obtain viable Lig3-null cells, left open the possibil-
ity that Lig3 could have a critical role in nuclear DNAmetabolism. The
generation of viable and healthy Lig3-null cells by providing a mito-
chondrial ligase conclusively rules out an essential role for Lig3 in the
nucleus.
The well-documented interaction between Lig3 and Xrcc1 had sug-
gested that Lig3 would be critical for the same nuclear DNA repair
pathways as Xrcc1, similar to the Lig4–Xrcc4 complex in DSB repair1.
However, the lack of sensitivity of Lig3-null cells to the spectrum of
DNA-damaging agents that sensitize Xrcc1-deficient cells, as shown
here in proliferating cells and in the accompanying paper in quiescent
cells27, together with a normal SCE frequency, provides strong evid-
ence that Lig3 is not required for Xrcc1-dependent nuclear DNA
repair, pointing instead to a role for Lig1.
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Our results demonstrate instead that Lig3 is an essential gene
because of its requirement in mitochondria. However, Lig3 can be
replaced in mitochondria with Lig1, the mitochondrial ligase in lower
eukaryotes, with an algal viral ligase consisting solely of a catalytic core,
and even the NAD1-dependent E. coli LigA. Thus, these results attest
to the requirement for a functional DNA ligase, which trumps even
cofactor specificity.Why vertebrates developed a requirement for Lig3
is uncertain, but given our results, the additional domains found in
Lig3 do not appear to be essential for mitochondrial function, includ-
ing mtDNAmaintenance or repair of oxidative damage. These results
emphasize a surprising plasticity that mammalian cells have in their
mitochondrial DNA ligase requirement.
METHODS SUMMARY
Cell culture. To construct stable cell lines expressing various DNA ligases, 53 106
Lig3KO/cKOneo1 cells were electroporated with 12mg ligase expression vector at
800V, 3mF. Hygromycin-resistant clones were picked after incubation for 10days
in 150mgml21 hygromycin. Initial screening for exogenous ligase expression was
performed by PCR with reverse transcription (RT–PCR) using specific primers,
followedbywesternblotting. For deletionof the endogenousLig3allele, 53 106 cells
were electroporated with 5mg Cre recombinase vector at 250V, 950mF. Cells were
plated based on a serial dilution. After 7 days, colonies were picked and expanded,
and then replica plated into two 96-well plates. One plate was cultured with 200mg
ml21 G418, whereas the other plate was cultured in normal media. Clones that did
not grow in G418, but grew in normal media, have converted the Lig3cKOneo1 allele
to a Lig3KO allele. The genotype of these clones was confirmed by PCR.
Western blotting. Whole-cell extracts were prepared with Nonidet-P40 buffer
andwere run on a 7.5% (w/v) Tris-HCl SDSpage gel, blotted and then probedwith
Lig3 antibody clone 7 (BD Transduction Labs), which recognizes both the human
andmouse Lig3 proteins, or Lig1 antibody N-13 (Santa Cruz). a-Tubulin (Sigma)
was used as a loading control.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
DNA constructs. A vector containing WT human Lig3 complementary DNA
(cDNA) (with both mitochondrial and nuclear translation initiation sites), a gift
from K.W. Caldecott, was digested with NheI and XbaI and subcloned into the
NheI site of pCAGGS. As the cDNA contained a 51-bp linker located before the
nuclear translation initiation site, it was modified by site-directed mutagenesis to
remove the linker, with the primers 59-GTGGCCCCTGTGAGATGGCTGAGCA
ACG-39 and 59-CGTTGCTCAGCCATCTCACAGGGGCCAC-39 to restore an
unmodified Lig3 sequence, creating pCAGGS-Lig3. A Pgk-hygromycin resistance
genewas insertedat thePsiI site tocreatepCAGGS-Lig3-hyg.MtLig3was generated
by using site-directed mutagenesis to generate an M88T mutation in pCAGGS-
Lig3-hyg using the primers 59-GAGAGGCCCCTGTGAGACCGCTGAGCA-39
and 59-GAGAGGATCCCTAGCAGGGAGCTACCAGTCTC-39. For NucLig3,
amino acids 1–87 were deleted by introducing NotI and BamHI sites into
pCAGGS-Lig3-hyg by PCR using the primers 59-GCATGCGGCCGCCTGTGAG
ATGGCTGAGCAACGGT-39, 59-GGATGGATCCCTAGCAGGGAGCTACCA
GTC-39. For the DBRCT mutation, amino acids 934–1009 were deleted by intro-
ducing NheI and MfeI sites by PCR using the primers 59-GGCCGCTAGCG
GGCAGCTATATGTCTTTGGCTTTCAAGAT-39 and 59-GAGACAATTGTTA
CTATACCTTTGTTTGGCACAGCGTC-39. The DZnF mutation was generated
by deleting amino acids 89–258 using site-directed mutagenesis with primers
59-TGGCCCCTGTGAGATGAAGGACTGTCTGCTAC-39 and 59-GTAGCAG
ACAGTCCTTCATCTCACAGGGGCCA-39. For GFP tagging of the Mt-tagged
constructs, SacII and AgeI sites were introduced and stop codons of the full-length
or DBRCT proteins were converted into alanine codons by PCR and cloned in
frame into SacII and AgeI sites of pEGFP-N1 (Clontech). PCR primers for full
length were 59-ACGGTACCGCGGCAGCTATATGTCTTTGG-39and 59-ACGG
TACCGCGGCAGCTATATGTCTTTGG-39, and forDBRCTwere 59-ACGGTAC
CGCGGCAGCTATATGTCTTTGG-39 and 59-GGCGACCGGTGGTACCTTT
GTTTGGCACAGCG-39.
For other constructs with GFP fusions (NucLig3, Lig3, DZnF and K508V),
plasmids were digested with PmlI and ligated into the vector backbone of
MtLig3-GFP using the same enzyme. The MAPKK NES21 was fused to the C
terminus of GFP by PCR using the primers 59-GCCCCCTCAGCCAGTACC
AAGAA-39 and 59-GGCCAATTGGCCTTATTACTGCTGCTCGTCCAGCTC
CAGCTCCTCCAGCTTCTTTTGGAGGTCCACGAGATTCTTGTACAGCTCG
TCCAT-39. Mouse Lig1 cDNA (Invitrogen) was amplified with primers intro-
ducing KpnI and AgeI sites and changing a stop codon into an alanine codon; this
fragment was cloned in frame into the KpnI and AgeI sites of pEGFP-N1. The Lig3
MLS was amplified with the primers 59-GGCGAATTCTATATGTCTTTGGC
TTTCAAGATCTTCTTTC-39and 59-ATTGGTACCCCTCACAGGGGCCACTG
CAG-39 and cloned into the EcoRI and KpnI sites of Lig1-GFP-hyg vector. The
Chlorella virus DNA ligase coding region was amplified with ChV-NheI and ChV-
MfeI primers and cloned into the NheI and MfeI sites of the pCAGGS-Lig1-Hyg
vector. ChV-NheI: 59-GCCGCTAGCACCATGGCAATCACAAAGCCATT-39;
ChV-MfeI: 59-GCCCAATTGTTAACGGTCTTCCTCGTGAC-39. The E. coli
DNA ligase coding region was amplified with LigA-NheI and LigA-MfeI primers
and cloned into the NheI and MfeI sites of the pCAGGS-Lig1-Hyg vector. LigA-
NheI: 59-GCCGCTAGCACCATGGAATCAATCGAACAACAA-39; LigA-MfeI:
59-GCCCAATTGTCAGCTACCCAGCAAACG-39.
RT–PCR.Hygromycin-resistant clones were screened by RT–PCR using primers
specific to human Lig3. A primer pair was used with the forward primer to the
pCAGGS backbone and the reverse primer to exon 3 of human Lig3, resulting in a
size difference for mitochondrial and nuclear forms (Supplementary Fig. 3):
pCAGRTfw 59-CAACGTGCTGGTTATTGTGC-39, hLig3Rv 59-ACAGCTTTC
TTCTTTGGTGTACCT-39. A similar strategy was used for Lig1, with primers
pCAGRTfw and Lig1RT_RV (59-ACCGCTGAGCAACGGTTCT-39), for
Chlorella virusDNA ligase, with primers pCAGRTfw and chlRTPCR-RV1 (59-CA
GCACTTGTGGTGTCTTGAA-39) and for E. coli DNA ligase, with primers
pCAGRTfw and LigARTPCR-RV1 (59-CCTGCACACGTTTGTTGAAA-39).
RNA was isolated using RNeasy Mini Kit (Qiagen) and cDNA was generated by
the SuperScript III First-strand Synthesis system (Invitrogen).
Genotyping. Genomic DNA was isolated using the Genelute Mammalian
Genomic DNA Miniprep Kit (Sigma). Each primer was named for the location
on the genomic DNA (for example, Int5-6Fw means that the primer is at the
intron between exons 5 and 6). Primer pairs used for genotyping were as follows:
Exon 5Fw and Neo2Rv (primer pair ‘a’ in Fig. 1a), 59-GGCTTTCACGGTG
ATGTGTA-39 and 59-TCTGGATTCATCGACTGTGG-39, using an annealing
temperature of 62 uC; Int5-6Fw and Int16-17Rv (primer pair ‘b’ in Fig. 1a),
59-CGGGTGTAGGGAGGTCATAA-39, 59-GAAGGAAGAGGTCTCCAGCA-39,
using an annealing temperature of 62 uC; Int10-11Fw and Int11-12Rv (primer
pair ‘c’ in Fig. 1a), 59-CACTAAACGTGGCAGAGCAA-39, 59-CCAGCCCA
GACTACAGCTTC-39, using an annealing temperature of 62 uC; Int5-6Fw2
and Int5-6Rv (Supplementary Fig. 1d), 59-GCCAAGTGTGAATATACAGC-39
and 59-CAGGGAGCTTGGGACGGATGC-39, using an annealing temperature
of 64 uC; Int5-6 and Int16-17(Supplementary Fig. 1d), 59-CGGGTGTAGGGA
GGTCATAA-39 and59-GAAGGAAGAGGTCTCCAGCA-39, using an annealing
temperature of 64 uC.
Microscopy.The subcellular localization of the various GFP fusion constructs was
checked by Mitotracker Red CMXRos (Invitrogen) and Hoechst 33342
(Invitrogen) to stain mitochondria and nucleus, respectively. DNA constructs
were transiently transfected with Lipofectamine 2000 (Invitrogen). After incub-
ating cells with Opti-MEM (Invitrogen) containing 10 nM Mitotracker Red
CMXRos and 2.5mM Hoechst 33342 for 20min at 37 uC, cells were monitored
with a Zeiss LSM 510 META laser scanning microscope.
qPCR mtDNA repair assay.One million mES cells with the indicated genotypes
were plated on 6-cm2 plates. After 16 h, cells were cultured with 6.25ml, 175mM
hydrogen peroxide for 15min and then cultured with conditioned medium for
1.5 h. mtDNA copy number andmtDNA repair were determined by a long-range
qPCR assay17. Basically, DNA was extracted from pellets of 13 106 cells with the
DNeasy Blood and Tissue kit (Qiagen) by a QIAcube automated DNA extraction
robot (Qiagen). Initial DNA concentration was measured using PicoGreen dou-
ble-stranded DNA binding agent (Invitrogen) and a DNA standard curve. Total
mouse genomic DNA at an approximate final concentration of 4.5 ngml21 was
then digested with with HaeII (New England Biosciences) for 1 h at 37 uC in a
reaction mixture containing13 NEBuffer 4, 13 BSA and 20U undiluted HaeII
enzyme. HaeII linearizes the mouse mtDNA by digesting once (2604) near the
D-loop region. Linearization of mitochondrial DNA ensures efficient amplifica-
tion and allows accurate determination of mtDNA copy number. After digestion,
DNA concentration was measured with PicoGreen and an appropriate volume
was directly removed from the digest to use for qPCR, with less than 5% variability
in DNA concentration between samples.
The qPCR reaction was performed with the GeneAmp XL PCR kit (Applied
Biosystems) as follows: 10–15ng total DNA, in a reaction mix of 50ml, with 13
buffer, 100ngml21 BSA, dNTPs at 200mM for each nucleotide, 1.2 and 1.1mM
MgO(Ac)2 for the long and short fragments, respectively, and 20 pmol for each of
two primers. Primer pairs for a 10-kb fragment ofmtDNA (long) and for a 117-bp
fragment of mtDNA (short) were used for calculating mtDNA damage and
mtDNA copy number, respectively. Primer sequences are as described prev-
iously17. DNA polymerase was added at a concentration of 1U per reaction. A
50% control and a ‘no template’ blank were used to ensure that the assay was
within quantitative range and free of contamination, respectively. PCR products
were quantified using fluorescence-blankmeasurements from the PicoGreen dou-
ble-stranded DNA binding agent. PCR products from the long fragment were
normalized to the short fragment to account for the effect of differing mtDNA
copy number on amplification of the long fragment.
SCE. Five million mES cells with the indicated genotypes were plated on 10-cm2
plates. After 24 h, cells were cultured with 10mM bromodeoxyuridine for 20 h
(approximately two cell-cycle periods) and pulsed with 0.03mgml21 colcemid
for the final 30min. The cells were collected by centrifugation and exposed to
0.075mMKClhypotonic solution for 30min at 25 uC.The cells werewashed twice
with the fixative (methanol:acetic acid5 3:1) and suspended in a small volume of
the fixative. The cell suspension was dropped onto ice-cold glass slides and air-
dried at 60 uC for 2 h. Two days later, slides were incubated with 1mgml21
Hoechst 33258 in Sorensen’s phosphate buffer (38mM KH2PO4, 60mM
Na2HPO4, pH 7.0) for 10min, rinsed with 23 SSC buffer (300mM NaCl,
30mM Na3C6H5O7, pH 7.0) and then overlaid with coverslips. Slides were
exposed to black light (l5 352nm) at a distance of 1 cm for 20min. After removal
of coverslips, the slides were incubated in 23 SSC at 60 uC for 2 h and then stained
with 4% (v/v) Giemsa solution in Sorensen’s buffer for 10min, rinsed in water and
air-dried. A two-tailed unpaired t-test was used to analyse the data.
Drug sensitivity assays. Two thousand mES cells per well were seeded in 24-well
plates induplicate.After 24h, cellswere incubatedwith variousdrugs at the indicated
concentrations (Fig. 3a) for 24h in mES cell medium, except hydrogen peroxide
which was for 1 h. For irradiation, plates were exposed to the X-ray source from an
X-RAD 225C apparatus at a rate of 687 cGymin21. Six days later, cells were fixed
with a solution of 12.5% (v/v) acetic acid, 12.5% (v/v) methanol for 15min and then
stained with 1% (w/v) crystal violet. Afterwards, stained cells were treated with 0.1%
SDS in methanol and the absorbance was measured at 595nm. Each point in the
plotswas the average of two experimentswhere each experiment had a duplicate and
was a percentage of the absorbance from untreated embryonic stem cells. For Lig3-
null cells expressing the Lig3 DZNF-GFP, MtLig3-DBRCT-GFP-NES and MtLig1
GFP transgenes, two independent null clones were used for each. For the colony
formation assays (Fig. 3b), 23 103 embryonic stemcellswere plated in 10-cm2plates
and exposed to ionizing radiation or ultraviolet C radiation. Eight days later, sur-
viving colonies were fixed with methanol and stained with 3% (v/v) Giemsa.
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